Evidence summary

Wheezing in children is common and the differential diagnosis is broad. The many potential causes include upper respiratory infection, asthma, cystic fibrosis, foreign body aspiration, vascular ring, tracheomalacia, primary immunodeficiency, and congenital heart disease.¹

Outpatient primary care cohort studies estimate that about half of children wheeze before they reach school age. Only one-third of children who wheeze during the first 3 years of life, however, continue to wheeze into later childhood and young adulthood.^2-4

These findings have led some experts to suggest that not all wheezing in children is asthma and that asthma exists in variant forms.^5-7 Variant wheezing patterns include transient early wheezing, which seems to be most prevalent in the first 3 years of life; wheezing without atopy, which occurs most often at 3 to 6 years of age; and wheezing with immunoglobulin E-associated atopy, which gradually increases in prevalence from birth and dominates in the over-6 age group. It is children in this last group whom we generally consider to have asthma.

Objective measures of lung function are challenging to perform in young children. Clinical signs and symptoms thus suggest the diagnosis of asthma.

Atopy, rhinitis, and eczema most often accompany persistent wheezing
Primary care cohort studies provide the best available evidence on which findings in infants and toddlers most likely predict persistent airway disease in childhood. A whole-population cohort study followed nearly all children born on the Isle of Wight from January 1989 through February 1990 to evaluate the natural history of childhood wheezing and to study associated risk factors.⁸ Children were seen at birth and at 1, 2, 4, and 10 years of age.

Findings most associated with current wheezing (within the last year) in 10-year-olds were atopy (odds ratio [OR]=4.38; 95% confidence interval [CI], 3.07-6.25), rhinitis (OR=3.72; 95% CI, 2.21-6.27), and eczema (OR=3.04; 95% CI, 2.05-4.51).⁸

An index to predict asthma
Since 1980, the Tucson Children’s Respiratory Study has followed 1246 healthy newborns seen by pediatricians affiliated with a large HMO in Tucson, Arizona. Questionnaires about parental asthma history and prenatal smoking history were obtained at enrollment. Childhood wheezing and its frequency, as well as physician-diagnosed allergies or asthma, were assessed at ages 2 and 3. If the child had wheezed in the past year, then the child was considered to be an “early wheezer.” If the frequency was 3 or more on a 5-point scale, then the child was considered to be an “early frequent wheezer.” Questionnaires were re-administered at ages 6, 8, 11, and 13. Three episodes of wheezing within the past year or a physician diagnosis of asthma with symptoms in the past year was considered “active asthma.” Blood specimens for eosinophils were obtained at age 10.

Using these data, the researchers developed stringent and loose criteria (TABLE 1) and odds ratios (TABLES 2 and 3) for childhood factors most predictive of an asthma diagnosis at an older age. The findings of the study may help clinicians care for wheezing infants and toddlers.⁹

TABLE 1
A clinical index of asthma risk⁹*

TABLE 2
Likelihood of active asthma predicted by stringent index⁹

TABLE 3
Likelihood of active asthma predicted by loose index⁹

Recommendations

A European and United States expert panel guide to the diagnosis and treatment of asthma in childhood, PRACTALL, states that “asthma should be suspected in any infant with recurrent wheezing and cough episodes. Frequently, diagnosis is possible only through long-term follow-up, consideration of the extensive differential diagnoses, and by observing the child’s response to bronchodilator and/or anti-inflammatory treatment.”¹⁰

The National Asthma Education and Prevention Program’s Expert Panel Report 3 (EPR-3) notes that diagnostic evaluation for asthma in children 0 to 4 years of age should include history, symptoms, physical examination, and assessment of quality of life.¹

Evidence summary

Wheezing in children is common and the differential diagnosis is broad. The many potential causes include upper respiratory infection, asthma, cystic fibrosis, foreign body aspiration, vascular ring, tracheomalacia, primary immunodeficiency, and congenital heart disease.¹

Outpatient primary care cohort studies estimate that about half of children wheeze before they reach school age. Only one-third of children who wheeze during the first 3 years of life, however, continue to wheeze into later childhood and young adulthood.^2-4

These findings have led some experts to suggest that not all wheezing in children is asthma and that asthma exists in variant forms.^5-7 Variant wheezing patterns include transient early wheezing, which seems to be most prevalent in the first 3 years of life; wheezing without atopy, which occurs most often at 3 to 6 years of age; and wheezing with immunoglobulin E-associated atopy, which gradually increases in prevalence from birth and dominates in the over-6 age group. It is children in this last group whom we generally consider to have asthma.

Objective measures of lung function are challenging to perform in young children. Clinical signs and symptoms thus suggest the diagnosis of asthma.

Atopy, rhinitis, and eczema most often accompany persistent wheezing
Primary care cohort studies provide the best available evidence on which findings in infants and toddlers most likely predict persistent airway disease in childhood. A whole-population cohort study followed nearly all children born on the Isle of Wight from January 1989 through February 1990 to evaluate the natural history of childhood wheezing and to study associated risk factors.⁸ Children were seen at birth and at 1, 2, 4, and 10 years of age.

Findings most associated with current wheezing (within the last year) in 10-year-olds were atopy (odds ratio [OR]=4.38; 95% confidence interval [CI], 3.07-6.25), rhinitis (OR=3.72; 95% CI, 2.21-6.27), and eczema (OR=3.04; 95% CI, 2.05-4.51).⁸

An index to predict asthma
Since 1980, the Tucson Children’s Respiratory Study has followed 1246 healthy newborns seen by pediatricians affiliated with a large HMO in Tucson, Arizona. Questionnaires about parental asthma history and prenatal smoking history were obtained at enrollment. Childhood wheezing and its frequency, as well as physician-diagnosed allergies or asthma, were assessed at ages 2 and 3. If the child had wheezed in the past year, then the child was considered to be an “early wheezer.” If the frequency was 3 or more on a 5-point scale, then the child was considered to be an “early frequent wheezer.” Questionnaires were re-administered at ages 6, 8, 11, and 13. Three episodes of wheezing within the past year or a physician diagnosis of asthma with symptoms in the past year was considered “active asthma.” Blood specimens for eosinophils were obtained at age 10.

Using these data, the researchers developed stringent and loose criteria (TABLE 1) and odds ratios (TABLES 2 and 3) for childhood factors most predictive of an asthma diagnosis at an older age. The findings of the study may help clinicians care for wheezing infants and toddlers.⁹

TABLE 1
A clinical index of asthma risk⁹*

TABLE 2
Likelihood of active asthma predicted by stringent index⁹

TABLE 3
Likelihood of active asthma predicted by loose index⁹

Recommendations

A European and United States expert panel guide to the diagnosis and treatment of asthma in childhood, PRACTALL, states that “asthma should be suspected in any infant with recurrent wheezing and cough episodes. Frequently, diagnosis is possible only through long-term follow-up, consideration of the extensive differential diagnoses, and by observing the child’s response to bronchodilator and/or anti-inflammatory treatment.”¹⁰

The National Asthma Education and Prevention Program’s Expert Panel Report 3 (EPR-3) notes that diagnostic evaluation for asthma in children 0 to 4 years of age should include history, symptoms, physical examination, and assessment of quality of life.¹

Evidence summary

Wheezing in children is common and the differential diagnosis is broad. The many potential causes include upper respiratory infection, asthma, cystic fibrosis, foreign body aspiration, vascular ring, tracheomalacia, primary immunodeficiency, and congenital heart disease.¹

Outpatient primary care cohort studies estimate that about half of children wheeze before they reach school age. Only one-third of children who wheeze during the first 3 years of life, however, continue to wheeze into later childhood and young adulthood.^2-4

These findings have led some experts to suggest that not all wheezing in children is asthma and that asthma exists in variant forms.^5-7 Variant wheezing patterns include transient early wheezing, which seems to be most prevalent in the first 3 years of life; wheezing without atopy, which occurs most often at 3 to 6 years of age; and wheezing with immunoglobulin E-associated atopy, which gradually increases in prevalence from birth and dominates in the over-6 age group. It is children in this last group whom we generally consider to have asthma.

Objective measures of lung function are challenging to perform in young children. Clinical signs and symptoms thus suggest the diagnosis of asthma.

Atopy, rhinitis, and eczema most often accompany persistent wheezing
Primary care cohort studies provide the best available evidence on which findings in infants and toddlers most likely predict persistent airway disease in childhood. A whole-population cohort study followed nearly all children born on the Isle of Wight from January 1989 through February 1990 to evaluate the natural history of childhood wheezing and to study associated risk factors.⁸ Children were seen at birth and at 1, 2, 4, and 10 years of age.

Findings most associated with current wheezing (within the last year) in 10-year-olds were atopy (odds ratio [OR]=4.38; 95% confidence interval [CI], 3.07-6.25), rhinitis (OR=3.72; 95% CI, 2.21-6.27), and eczema (OR=3.04; 95% CI, 2.05-4.51).⁸

An index to predict asthma
Since 1980, the Tucson Children’s Respiratory Study has followed 1246 healthy newborns seen by pediatricians affiliated with a large HMO in Tucson, Arizona. Questionnaires about parental asthma history and prenatal smoking history were obtained at enrollment. Childhood wheezing and its frequency, as well as physician-diagnosed allergies or asthma, were assessed at ages 2 and 3. If the child had wheezed in the past year, then the child was considered to be an “early wheezer.” If the frequency was 3 or more on a 5-point scale, then the child was considered to be an “early frequent wheezer.” Questionnaires were re-administered at ages 6, 8, 11, and 13. Three episodes of wheezing within the past year or a physician diagnosis of asthma with symptoms in the past year was considered “active asthma.” Blood specimens for eosinophils were obtained at age 10.

Using these data, the researchers developed stringent and loose criteria (TABLE 1) and odds ratios (TABLES 2 and 3) for childhood factors most predictive of an asthma diagnosis at an older age. The findings of the study may help clinicians care for wheezing infants and toddlers.⁹

TABLE 1
A clinical index of asthma risk⁹*

TABLE 2
Likelihood of active asthma predicted by stringent index⁹

TABLE 3
Likelihood of active asthma predicted by loose index⁹

Recommendations

A European and United States expert panel guide to the diagnosis and treatment of asthma in childhood, PRACTALL, states that “asthma should be suspected in any infant with recurrent wheezing and cough episodes. Frequently, diagnosis is possible only through long-term follow-up, consideration of the extensive differential diagnoses, and by observing the child’s response to bronchodilator and/or anti-inflammatory treatment.”¹⁰

The National Asthma Education and Prevention Program’s Expert Panel Report 3 (EPR-3) notes that diagnostic evaluation for asthma in children 0 to 4 years of age should include history, symptoms, physical examination, and assessment of quality of life.¹

CASE Mary S, an 82-year-old patient you recently treated for bronchitis with a 3-day course of levofloxacin, calls your office complaining of diarrhea and abdominal cramps. She describes the diarrhea as nonbloody and particularly foul smelling and asks if she can take loperamide for her symptoms.

If Mary S were your patient, what would you tell her?

The incidence of Clostridium difficile infection (CDI) has been on the rise since 2000, when a common epidemic strain began circulating in North America.¹ Although hospitalization or residency in a long-term care facility remains a classic risk factor for CDI, physicians in out-patient settings are increasingly likely to see patients with community-acquired CDI.

Recently updated guidelines from the Society for Health-care Epidemiology of America (SHEA) and the Infectious Diseases Society of America define CDI as the presence of diarrhea (≥3 unformed stools in 24 hours) and either a positive stool test for toxigenic C difficile or its toxins or colonoscopic or histopathologic findings demonstrating pseudomembranous colitis.² That said, the clinical features of CDI are nonspecific and many patients do not fit the classic profile. So diagnosing CDI requires a high index of suspicion.

The text and tables that follow detail some surprising things about who is likely to develop CDI and which treatment options to employ (and, in some cases, avoid).

Is it CDI? Looking beyond the obvious

Antibiotic use and advanced age, like hospitalization, are classic risk factors for CDI.³ Diarrhea typically begins during or shortly after a course of antibiotics, but may develop as long as 8 weeks after treatment is completed. While any antibiotic, including metronidazole, can precipitate CDI, clindamycin, cephalosporins, extended-spectrum penicillins, and quinolones are most frequently implicated.⁴ Epidemiologic studies have suggested an association between gastric acid-reducing agents—primarily proton-pump inhibitors—and CDI.^4-7 But this link remains controversial, as other investigations have not found a clear relationship.⁸

In addition to diarrhea, approximately 28% of patients with CDI develop a fever (as high as 104°F); 50% develop leukocytosis (up to 50,000 cells/mcL); and 22% develop abdominal pain, usually localized to the lower quadrants.⁹ These symptoms, however, are not specific to C difficile, and could be due to a different enteric pathogen, intra-abdominal sepsis, inflammatory bowel disease, or adverse effects of medication, among other causes.⁹

Markers for severe CDI include age >70 years, leukocyte count >20,000 cells/mcL, albumin level <2.5 g/dL, small-bowel obstruction or ileus, and a computed tomography (CT) scan showing colorectal inflammation.¹⁰ Severe CDI can lead to toxic megacolon, bowel perforation, sepsis, and even death.

In addition to considering CDI in patients with nonspecific symptoms, it is important to include it in the differential diagnosis of patients who do not fit the classic profile. In a recent study of patients with CDI at 4 Veterans Affairs facilities, almost half (49%) of those studied had no exposure to antimicrobial drugs. The researchers further found that the median age of patients with CDI was 61 years—younger than that found in previous studies—and that 20% of the cases were community-acquired.¹¹

Consider CDI in children, too. Risk factors for CDI in pediatric patients include disruption of the normal microflora of the gastrointestinal tract, compromised immune status, poor diet, underlying health conditions, concurrent infections, and cancer.¹²

Diagnostic testing: Consider a 2-step assay

Patients with symptoms suggestive of CDI should undergo laboratory testing to confirm the diagnosis. TABLE 1 lists the tests that are widely available in the United States.³ Only liquid stools should be tested and just one sample should be sent to the lab, as multiple samples do not increase the diagnostic yield.¹³ In addition, tests should be used only for diagnosis, and not as a “test of cure.” This is because patients can shed C difficile toxin and spores for several weeks after completing treatment, and there are wide variations in the sensitivity of toxin assays.

Infants <1 year old have high rates of asymptomatic toxigenic strains of C difficile, and until 2008, recommendations from SHEA discouraged testing the stools of such young patients. Because of the difficulty in differentiating incidental colonization from true CDI in this patient population, the authors of a recent review suggested using more than one diagnostic approach when testing children <1 year of age.¹⁴

We advocate a 2-step assay—that is, testing for both glutamate dehydrogenase (GDH)—an antigen common to all strains of C difficile—and C difficile toxins A and B. The common antigen test is sensitive, but may detect carriers who do not have active disease. The enzyme immunoassay (EIA) for toxins A and B helps to improve specificity. Therefore, positive results of both tests would be considered a positive finding, negative results of both tests would be considered a negative finding, and one positive result with one negative result would require another test for toxin detection.³

The reverse-transcriptase polymerase chain reaction (RT-PCR) assay, which detects the toxin B gene of C difficile, is the newest test for CDI. The RT-PCR assay detects only toxigenic strains of C difficile, and all toxigenic strains produce toxin B, making it more specific than testing for the common antigen. The RT-PCR assay also has better sensitivity than the cytotoxin assay, which also tests for toxin B. The major limitation of the RT-PCR assay is the frequency of false-positive results in hospitalized patients with a high incidence of C difficile colonization.³

Routine laboratory studies, including a complete blood count with differential and a complete metabolic panel, are often useful to ascertain the presence and degree of leukocytosis, dehydration, and other metabolic abnormalities and to test for hypoalbuminemia. Fecal leukocytes can be seen in colitis and may be useful in select cases.

Imaging studies such as radiography, CT, and endoscopy have largely been superseded by lab testing for CDI. Plain radiographs are usually normal in patients with CDI, unless the patient has an ileus or toxic megacolon. CT is useful, however, in suspected cases of fulminant CDI or toxic megacolon, and may reveal colonic-wall thickening, pericolonic stranding, or ascites.⁹ Colonoscopy is preferred over sigmoidoscopy because up to one-third of patients with pseudomembranous colitis will have involvement of the right colon only.⁹ However, this test carries the risk of perforation in patients with fulminant colitis.

TABLE 1
Lab tests for C difficile infection

Treatment: What to consider, what to avoid

Of the 2 antibiotics most commonly used to treat CDI—metronidazole and vancomycin—only the latter has been approved by the US Food and Drug Administration for this indication. Nevertheless, metronidazole is generally recommended as first-line therapy and has the advantage of being much less expensive than vancomycin. However, an RCT found that oral vancomycin was superior to metronidazole in patients with severe disease.¹⁵ The time to resolution of diarrhea may be shorter with oral vancomycin than with metronidazole, as well.¹⁶

Recent guidelines suggest that clinicians consider 3 factors in deciding how to treat a first episode of CDI: the patient’s age, peak white blood cell count, and peak serum creatinine level.² TABLE 2 presents an overview of treatment recommendations for both an initial episode of CDI and recurrences.

Treat severe CDI without delay. For patients with suspected severe CDI, treatment should be started empirically, without waiting for test results. Avoid antiperistaltic agents, which can obscure symptoms and precipitate toxic megacolon.² Discontinue an antibiotic, if the patient is taking one, as soon as possible after the original infection has been adequately treated. If other infections need to be treated concurrently, we recommend that the course of treatment for CDI be extended until after the other antibiotic regimens have been stopped.

Avoid probiotics in this group. The use of probiotics, both for prevention and to help restore normal bowel flora in patients with CDI, has been advocated for many years. One RCT showed that a yogurt drink containing Lactobacillus and other bacteria reduced the risk of CDI in individuals ≥50 years of age who were taking antibiotics,¹⁷ but the guideline development panel recommended against using probiotics until larger trials have been completed.²

Probiotics are not without risk, and several cases of bacteremia have been reported.^18,19 Immunocompromised patients appear to be at comparably higher risk, and probiotics should be avoided in this group. Numerous adjunctive agents, including intraluminal toxin binders, biotherapeutic agents, monoclonal antibodies, and a C difficile vaccine, are in various stages of development.²

How to handle recurrences

Relapse rates for CDI range from 6% to 25%,² and affect patients who receive either vancomycin or metronidazole for the initial treatment. The mechanism relates to either relapse of the original infection or reinfection of susceptible patients with a new strain of C difficile.

Risk of relapse. Elderly patients treated with metronidazole seem to be particularly susceptible to CDI relapse.²⁰ Other risk factors include the administration of non-C difficile antibiotics during or after treatment of CDI, a defective immune response against toxin A, glucocorticoid use, prior stroke, and concurrent use of a proton-pump inhibitor.^21-25

TABLE 2 lists tapering and/or pulsed dosing of oral vancomycin as treatment for patients with a second recurrence. We often prescribe the following 6-week regimen, telling patients to take 125 mg vancomycin:

• 4 times a day for one week,
• then 2 times a day for one week,
• then once a day for one week,
• then every other day for one week, and
• finally, every 72 hours for 2 weeks.

Oral metronidazole should not be used beyond the first recurrence or for long-term therapy because of cumulative neurotoxicity, which can be irreversible.²

Management of patients whose CDI recurs after a long course of vancomycin is challenging. Oral rifaximin therapy (400 mg twice a day for 14 days), started immediately at the end of the oral vancomycin course, was shown to cure 7 of 8 patients with multiple relapses.²⁶ Other potential treatment options are oral nitazoxanide, IV tigecycline, or IV immunoglobulin.

CASE You explain to Mary S that diagnostic tests are needed before you can determine whether she can safely take loperamide. When she comes in later that day, you collect a stool sample for C difficile antigen and toxin testing, and order a complete blood count and electrolyte panel.

The patient’s C difficile tests come back positive, her white blood cell count is <15,000 cells/mcL, and her creatinine level is ≤1.5 times her baseline, so you start her on oral metronidazole 500 mg every 8 hours for 14 days. (If the antigen assay had been positive and the toxin negative, you would have either repeated the test or treated Mary S empirically with metronidazole. If the initial antigen assay had been negative, you would have advised her to take the loperamide.)

You schedule a follow-up visit a day or 2 after starting therapy. If the patient is dehydrated or her symptoms have not improved by then, hospitalization may be required.

TABLE 2
Treatment recommendations for C difficile infection

CORRESPONDENCE
Richard R. Watkins, MD, MS, Division of Infectious Diseases, Akron General Medical Center, 224 West Exchange Street, Suite 290, Akron, OH 44302; [email protected]

CASE Mary S, an 82-year-old patient you recently treated for bronchitis with a 3-day course of levofloxacin, calls your office complaining of diarrhea and abdominal cramps. She describes the diarrhea as nonbloody and particularly foul smelling and asks if she can take loperamide for her symptoms.

If Mary S were your patient, what would you tell her?

The incidence of Clostridium difficile infection (CDI) has been on the rise since 2000, when a common epidemic strain began circulating in North America.¹ Although hospitalization or residency in a long-term care facility remains a classic risk factor for CDI, physicians in out-patient settings are increasingly likely to see patients with community-acquired CDI.

Recently updated guidelines from the Society for Health-care Epidemiology of America (SHEA) and the Infectious Diseases Society of America define CDI as the presence of diarrhea (≥3 unformed stools in 24 hours) and either a positive stool test for toxigenic C difficile or its toxins or colonoscopic or histopathologic findings demonstrating pseudomembranous colitis.² That said, the clinical features of CDI are nonspecific and many patients do not fit the classic profile. So diagnosing CDI requires a high index of suspicion.

The text and tables that follow detail some surprising things about who is likely to develop CDI and which treatment options to employ (and, in some cases, avoid).

Is it CDI? Looking beyond the obvious

Antibiotic use and advanced age, like hospitalization, are classic risk factors for CDI.³ Diarrhea typically begins during or shortly after a course of antibiotics, but may develop as long as 8 weeks after treatment is completed. While any antibiotic, including metronidazole, can precipitate CDI, clindamycin, cephalosporins, extended-spectrum penicillins, and quinolones are most frequently implicated.⁴ Epidemiologic studies have suggested an association between gastric acid-reducing agents—primarily proton-pump inhibitors—and CDI.^4-7 But this link remains controversial, as other investigations have not found a clear relationship.⁸

In addition to diarrhea, approximately 28% of patients with CDI develop a fever (as high as 104°F); 50% develop leukocytosis (up to 50,000 cells/mcL); and 22% develop abdominal pain, usually localized to the lower quadrants.⁹ These symptoms, however, are not specific to C difficile, and could be due to a different enteric pathogen, intra-abdominal sepsis, inflammatory bowel disease, or adverse effects of medication, among other causes.⁹

Markers for severe CDI include age >70 years, leukocyte count >20,000 cells/mcL, albumin level <2.5 g/dL, small-bowel obstruction or ileus, and a computed tomography (CT) scan showing colorectal inflammation.¹⁰ Severe CDI can lead to toxic megacolon, bowel perforation, sepsis, and even death.

In addition to considering CDI in patients with nonspecific symptoms, it is important to include it in the differential diagnosis of patients who do not fit the classic profile. In a recent study of patients with CDI at 4 Veterans Affairs facilities, almost half (49%) of those studied had no exposure to antimicrobial drugs. The researchers further found that the median age of patients with CDI was 61 years—younger than that found in previous studies—and that 20% of the cases were community-acquired.¹¹

Consider CDI in children, too. Risk factors for CDI in pediatric patients include disruption of the normal microflora of the gastrointestinal tract, compromised immune status, poor diet, underlying health conditions, concurrent infections, and cancer.¹²

Diagnostic testing: Consider a 2-step assay

Patients with symptoms suggestive of CDI should undergo laboratory testing to confirm the diagnosis. TABLE 1 lists the tests that are widely available in the United States.³ Only liquid stools should be tested and just one sample should be sent to the lab, as multiple samples do not increase the diagnostic yield.¹³ In addition, tests should be used only for diagnosis, and not as a “test of cure.” This is because patients can shed C difficile toxin and spores for several weeks after completing treatment, and there are wide variations in the sensitivity of toxin assays.

Infants <1 year old have high rates of asymptomatic toxigenic strains of C difficile, and until 2008, recommendations from SHEA discouraged testing the stools of such young patients. Because of the difficulty in differentiating incidental colonization from true CDI in this patient population, the authors of a recent review suggested using more than one diagnostic approach when testing children <1 year of age.¹⁴

We advocate a 2-step assay—that is, testing for both glutamate dehydrogenase (GDH)—an antigen common to all strains of C difficile—and C difficile toxins A and B. The common antigen test is sensitive, but may detect carriers who do not have active disease. The enzyme immunoassay (EIA) for toxins A and B helps to improve specificity. Therefore, positive results of both tests would be considered a positive finding, negative results of both tests would be considered a negative finding, and one positive result with one negative result would require another test for toxin detection.³

The reverse-transcriptase polymerase chain reaction (RT-PCR) assay, which detects the toxin B gene of C difficile, is the newest test for CDI. The RT-PCR assay detects only toxigenic strains of C difficile, and all toxigenic strains produce toxin B, making it more specific than testing for the common antigen. The RT-PCR assay also has better sensitivity than the cytotoxin assay, which also tests for toxin B. The major limitation of the RT-PCR assay is the frequency of false-positive results in hospitalized patients with a high incidence of C difficile colonization.³

Routine laboratory studies, including a complete blood count with differential and a complete metabolic panel, are often useful to ascertain the presence and degree of leukocytosis, dehydration, and other metabolic abnormalities and to test for hypoalbuminemia. Fecal leukocytes can be seen in colitis and may be useful in select cases.

Imaging studies such as radiography, CT, and endoscopy have largely been superseded by lab testing for CDI. Plain radiographs are usually normal in patients with CDI, unless the patient has an ileus or toxic megacolon. CT is useful, however, in suspected cases of fulminant CDI or toxic megacolon, and may reveal colonic-wall thickening, pericolonic stranding, or ascites.⁹ Colonoscopy is preferred over sigmoidoscopy because up to one-third of patients with pseudomembranous colitis will have involvement of the right colon only.⁹ However, this test carries the risk of perforation in patients with fulminant colitis.

TABLE 1
Lab tests for C difficile infection

Treatment: What to consider, what to avoid

Of the 2 antibiotics most commonly used to treat CDI—metronidazole and vancomycin—only the latter has been approved by the US Food and Drug Administration for this indication. Nevertheless, metronidazole is generally recommended as first-line therapy and has the advantage of being much less expensive than vancomycin. However, an RCT found that oral vancomycin was superior to metronidazole in patients with severe disease.¹⁵ The time to resolution of diarrhea may be shorter with oral vancomycin than with metronidazole, as well.¹⁶

Recent guidelines suggest that clinicians consider 3 factors in deciding how to treat a first episode of CDI: the patient’s age, peak white blood cell count, and peak serum creatinine level.² TABLE 2 presents an overview of treatment recommendations for both an initial episode of CDI and recurrences.

Treat severe CDI without delay. For patients with suspected severe CDI, treatment should be started empirically, without waiting for test results. Avoid antiperistaltic agents, which can obscure symptoms and precipitate toxic megacolon.² Discontinue an antibiotic, if the patient is taking one, as soon as possible after the original infection has been adequately treated. If other infections need to be treated concurrently, we recommend that the course of treatment for CDI be extended until after the other antibiotic regimens have been stopped.

Avoid probiotics in this group. The use of probiotics, both for prevention and to help restore normal bowel flora in patients with CDI, has been advocated for many years. One RCT showed that a yogurt drink containing Lactobacillus and other bacteria reduced the risk of CDI in individuals ≥50 years of age who were taking antibiotics,¹⁷ but the guideline development panel recommended against using probiotics until larger trials have been completed.²

Probiotics are not without risk, and several cases of bacteremia have been reported.^18,19 Immunocompromised patients appear to be at comparably higher risk, and probiotics should be avoided in this group. Numerous adjunctive agents, including intraluminal toxin binders, biotherapeutic agents, monoclonal antibodies, and a C difficile vaccine, are in various stages of development.²

How to handle recurrences

Relapse rates for CDI range from 6% to 25%,² and affect patients who receive either vancomycin or metronidazole for the initial treatment. The mechanism relates to either relapse of the original infection or reinfection of susceptible patients with a new strain of C difficile.

Risk of relapse. Elderly patients treated with metronidazole seem to be particularly susceptible to CDI relapse.²⁰ Other risk factors include the administration of non-C difficile antibiotics during or after treatment of CDI, a defective immune response against toxin A, glucocorticoid use, prior stroke, and concurrent use of a proton-pump inhibitor.^21-25

TABLE 2 lists tapering and/or pulsed dosing of oral vancomycin as treatment for patients with a second recurrence. We often prescribe the following 6-week regimen, telling patients to take 125 mg vancomycin:

• 4 times a day for one week,
• then 2 times a day for one week,
• then once a day for one week,
• then every other day for one week, and
• finally, every 72 hours for 2 weeks.

Oral metronidazole should not be used beyond the first recurrence or for long-term therapy because of cumulative neurotoxicity, which can be irreversible.²

Management of patients whose CDI recurs after a long course of vancomycin is challenging. Oral rifaximin therapy (400 mg twice a day for 14 days), started immediately at the end of the oral vancomycin course, was shown to cure 7 of 8 patients with multiple relapses.²⁶ Other potential treatment options are oral nitazoxanide, IV tigecycline, or IV immunoglobulin.

CASE You explain to Mary S that diagnostic tests are needed before you can determine whether she can safely take loperamide. When she comes in later that day, you collect a stool sample for C difficile antigen and toxin testing, and order a complete blood count and electrolyte panel.

The patient’s C difficile tests come back positive, her white blood cell count is <15,000 cells/mcL, and her creatinine level is ≤1.5 times her baseline, so you start her on oral metronidazole 500 mg every 8 hours for 14 days. (If the antigen assay had been positive and the toxin negative, you would have either repeated the test or treated Mary S empirically with metronidazole. If the initial antigen assay had been negative, you would have advised her to take the loperamide.)

You schedule a follow-up visit a day or 2 after starting therapy. If the patient is dehydrated or her symptoms have not improved by then, hospitalization may be required.

TABLE 2
Treatment recommendations for C difficile infection

CORRESPONDENCE
Richard R. Watkins, MD, MS, Division of Infectious Diseases, Akron General Medical Center, 224 West Exchange Street, Suite 290, Akron, OH 44302; [email protected]

CASE Mary S, an 82-year-old patient you recently treated for bronchitis with a 3-day course of levofloxacin, calls your office complaining of diarrhea and abdominal cramps. She describes the diarrhea as nonbloody and particularly foul smelling and asks if she can take loperamide for her symptoms.

If Mary S were your patient, what would you tell her?

The incidence of Clostridium difficile infection (CDI) has been on the rise since 2000, when a common epidemic strain began circulating in North America.¹ Although hospitalization or residency in a long-term care facility remains a classic risk factor for CDI, physicians in out-patient settings are increasingly likely to see patients with community-acquired CDI.

Recently updated guidelines from the Society for Health-care Epidemiology of America (SHEA) and the Infectious Diseases Society of America define CDI as the presence of diarrhea (≥3 unformed stools in 24 hours) and either a positive stool test for toxigenic C difficile or its toxins or colonoscopic or histopathologic findings demonstrating pseudomembranous colitis.² That said, the clinical features of CDI are nonspecific and many patients do not fit the classic profile. So diagnosing CDI requires a high index of suspicion.

The text and tables that follow detail some surprising things about who is likely to develop CDI and which treatment options to employ (and, in some cases, avoid).

Is it CDI? Looking beyond the obvious

Antibiotic use and advanced age, like hospitalization, are classic risk factors for CDI.³ Diarrhea typically begins during or shortly after a course of antibiotics, but may develop as long as 8 weeks after treatment is completed. While any antibiotic, including metronidazole, can precipitate CDI, clindamycin, cephalosporins, extended-spectrum penicillins, and quinolones are most frequently implicated.⁴ Epidemiologic studies have suggested an association between gastric acid-reducing agents—primarily proton-pump inhibitors—and CDI.^4-7 But this link remains controversial, as other investigations have not found a clear relationship.⁸

In addition to diarrhea, approximately 28% of patients with CDI develop a fever (as high as 104°F); 50% develop leukocytosis (up to 50,000 cells/mcL); and 22% develop abdominal pain, usually localized to the lower quadrants.⁹ These symptoms, however, are not specific to C difficile, and could be due to a different enteric pathogen, intra-abdominal sepsis, inflammatory bowel disease, or adverse effects of medication, among other causes.⁹

Markers for severe CDI include age >70 years, leukocyte count >20,000 cells/mcL, albumin level <2.5 g/dL, small-bowel obstruction or ileus, and a computed tomography (CT) scan showing colorectal inflammation.¹⁰ Severe CDI can lead to toxic megacolon, bowel perforation, sepsis, and even death.

In addition to considering CDI in patients with nonspecific symptoms, it is important to include it in the differential diagnosis of patients who do not fit the classic profile. In a recent study of patients with CDI at 4 Veterans Affairs facilities, almost half (49%) of those studied had no exposure to antimicrobial drugs. The researchers further found that the median age of patients with CDI was 61 years—younger than that found in previous studies—and that 20% of the cases were community-acquired.¹¹

Consider CDI in children, too. Risk factors for CDI in pediatric patients include disruption of the normal microflora of the gastrointestinal tract, compromised immune status, poor diet, underlying health conditions, concurrent infections, and cancer.¹²

Diagnostic testing: Consider a 2-step assay

Patients with symptoms suggestive of CDI should undergo laboratory testing to confirm the diagnosis. TABLE 1 lists the tests that are widely available in the United States.³ Only liquid stools should be tested and just one sample should be sent to the lab, as multiple samples do not increase the diagnostic yield.¹³ In addition, tests should be used only for diagnosis, and not as a “test of cure.” This is because patients can shed C difficile toxin and spores for several weeks after completing treatment, and there are wide variations in the sensitivity of toxin assays.

Infants <1 year old have high rates of asymptomatic toxigenic strains of C difficile, and until 2008, recommendations from SHEA discouraged testing the stools of such young patients. Because of the difficulty in differentiating incidental colonization from true CDI in this patient population, the authors of a recent review suggested using more than one diagnostic approach when testing children <1 year of age.¹⁴

We advocate a 2-step assay—that is, testing for both glutamate dehydrogenase (GDH)—an antigen common to all strains of C difficile—and C difficile toxins A and B. The common antigen test is sensitive, but may detect carriers who do not have active disease. The enzyme immunoassay (EIA) for toxins A and B helps to improve specificity. Therefore, positive results of both tests would be considered a positive finding, negative results of both tests would be considered a negative finding, and one positive result with one negative result would require another test for toxin detection.³

The reverse-transcriptase polymerase chain reaction (RT-PCR) assay, which detects the toxin B gene of C difficile, is the newest test for CDI. The RT-PCR assay detects only toxigenic strains of C difficile, and all toxigenic strains produce toxin B, making it more specific than testing for the common antigen. The RT-PCR assay also has better sensitivity than the cytotoxin assay, which also tests for toxin B. The major limitation of the RT-PCR assay is the frequency of false-positive results in hospitalized patients with a high incidence of C difficile colonization.³

Routine laboratory studies, including a complete blood count with differential and a complete metabolic panel, are often useful to ascertain the presence and degree of leukocytosis, dehydration, and other metabolic abnormalities and to test for hypoalbuminemia. Fecal leukocytes can be seen in colitis and may be useful in select cases.

Imaging studies such as radiography, CT, and endoscopy have largely been superseded by lab testing for CDI. Plain radiographs are usually normal in patients with CDI, unless the patient has an ileus or toxic megacolon. CT is useful, however, in suspected cases of fulminant CDI or toxic megacolon, and may reveal colonic-wall thickening, pericolonic stranding, or ascites.⁹ Colonoscopy is preferred over sigmoidoscopy because up to one-third of patients with pseudomembranous colitis will have involvement of the right colon only.⁹ However, this test carries the risk of perforation in patients with fulminant colitis.

TABLE 1
Lab tests for C difficile infection

Treatment: What to consider, what to avoid

Of the 2 antibiotics most commonly used to treat CDI—metronidazole and vancomycin—only the latter has been approved by the US Food and Drug Administration for this indication. Nevertheless, metronidazole is generally recommended as first-line therapy and has the advantage of being much less expensive than vancomycin. However, an RCT found that oral vancomycin was superior to metronidazole in patients with severe disease.¹⁵ The time to resolution of diarrhea may be shorter with oral vancomycin than with metronidazole, as well.¹⁶

Recent guidelines suggest that clinicians consider 3 factors in deciding how to treat a first episode of CDI: the patient’s age, peak white blood cell count, and peak serum creatinine level.² TABLE 2 presents an overview of treatment recommendations for both an initial episode of CDI and recurrences.

Treat severe CDI without delay. For patients with suspected severe CDI, treatment should be started empirically, without waiting for test results. Avoid antiperistaltic agents, which can obscure symptoms and precipitate toxic megacolon.² Discontinue an antibiotic, if the patient is taking one, as soon as possible after the original infection has been adequately treated. If other infections need to be treated concurrently, we recommend that the course of treatment for CDI be extended until after the other antibiotic regimens have been stopped.

Avoid probiotics in this group. The use of probiotics, both for prevention and to help restore normal bowel flora in patients with CDI, has been advocated for many years. One RCT showed that a yogurt drink containing Lactobacillus and other bacteria reduced the risk of CDI in individuals ≥50 years of age who were taking antibiotics,¹⁷ but the guideline development panel recommended against using probiotics until larger trials have been completed.²

Probiotics are not without risk, and several cases of bacteremia have been reported.^18,19 Immunocompromised patients appear to be at comparably higher risk, and probiotics should be avoided in this group. Numerous adjunctive agents, including intraluminal toxin binders, biotherapeutic agents, monoclonal antibodies, and a C difficile vaccine, are in various stages of development.²

How to handle recurrences

Relapse rates for CDI range from 6% to 25%,² and affect patients who receive either vancomycin or metronidazole for the initial treatment. The mechanism relates to either relapse of the original infection or reinfection of susceptible patients with a new strain of C difficile.

Risk of relapse. Elderly patients treated with metronidazole seem to be particularly susceptible to CDI relapse.²⁰ Other risk factors include the administration of non-C difficile antibiotics during or after treatment of CDI, a defective immune response against toxin A, glucocorticoid use, prior stroke, and concurrent use of a proton-pump inhibitor.^21-25

TABLE 2 lists tapering and/or pulsed dosing of oral vancomycin as treatment for patients with a second recurrence. We often prescribe the following 6-week regimen, telling patients to take 125 mg vancomycin:

• 4 times a day for one week,
• then 2 times a day for one week,
• then once a day for one week,
• then every other day for one week, and
• finally, every 72 hours for 2 weeks.

Oral metronidazole should not be used beyond the first recurrence or for long-term therapy because of cumulative neurotoxicity, which can be irreversible.²

Management of patients whose CDI recurs after a long course of vancomycin is challenging. Oral rifaximin therapy (400 mg twice a day for 14 days), started immediately at the end of the oral vancomycin course, was shown to cure 7 of 8 patients with multiple relapses.²⁶ Other potential treatment options are oral nitazoxanide, IV tigecycline, or IV immunoglobulin.

CASE You explain to Mary S that diagnostic tests are needed before you can determine whether she can safely take loperamide. When she comes in later that day, you collect a stool sample for C difficile antigen and toxin testing, and order a complete blood count and electrolyte panel.

The patient’s C difficile tests come back positive, her white blood cell count is <15,000 cells/mcL, and her creatinine level is ≤1.5 times her baseline, so you start her on oral metronidazole 500 mg every 8 hours for 14 days. (If the antigen assay had been positive and the toxin negative, you would have either repeated the test or treated Mary S empirically with metronidazole. If the initial antigen assay had been negative, you would have advised her to take the loperamide.)

You schedule a follow-up visit a day or 2 after starting therapy. If the patient is dehydrated or her symptoms have not improved by then, hospitalization may be required.

TABLE 2
Treatment recommendations for C difficile infection

CORRESPONDENCE
Richard R. Watkins, MD, MS, Division of Infectious Diseases, Akron General Medical Center, 224 West Exchange Street, Suite 290, Akron, OH 44302; [email protected]

Many physicians prescribe hypnotics for hospitalized patients with insomnia. Frequently used medications include temazepam, diphenhydramine, quetiapine, and trazodone. We have found hydroxyzine, 25 mg to 100 mg nightly, to be effective in adults and geriatric patients and feel it is a more rational choice.

Temazepam and other benzodiazepines may cause behavioral disinhibition, delirium (particularly in geriatric patients), and development of tolerance,¹ which may lead to withdrawal symptoms after discharge. Diphenhydramine, quetiapine, and trazodone are effective as hypnotics through antihistaminergic mechanisms, but efficacy can be compromised by adverse effects mediated by non-histaminergic receptor activity. For example, at doses used for sleep, quetiapine can cause weight gain,² extrapyramidal symptoms, and orthostasis. Trazodone also causes orthostasis and, infrequently, priapism. Because of its relatively high affinity for acetylcholine receptors, diphenhydramine can cause constipation and urinary retention, worsen cognitive function, and exacerbate delirium, particularly in geriatric patients.³

Hydroxyzine is a more selective anti-histamine than the aforementioned molecules,⁴ which leads to the sleep-promoting benefits of Hl-receptor blockade without significant alpha-1 adrenergic antagonism or anticholinergic side effects. The ratio of affinity for H1 receptors to cerebral acetylcholine receptors is more than 10 times greater for hydroxyzine than for diphenhydramine. Similarly, hydroxyzine has greater affinity for H1 receptors than alpha-1 adrenergic receptors, while trazodone has greater affinity for alpha-1 adrenergic receptors than for H1 receptors. Additionally, hydroxyzine does not lead to tolerance.⁵ Finally, it has a potential economic advantage over on-patent drugs such as quetiapine.

A disadvantage to hydroxyzine is its comparatively long half-life of 20 hours. Although this can lead to daytime sedation after nighttime dosing, we have not found this to be clinically significant for most patients.

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Many physicians prescribe hypnotics for hospitalized patients with insomnia. Frequently used medications include temazepam, diphenhydramine, quetiapine, and trazodone. We have found hydroxyzine, 25 mg to 100 mg nightly, to be effective in adults and geriatric patients and feel it is a more rational choice.

Temazepam and other benzodiazepines may cause behavioral disinhibition, delirium (particularly in geriatric patients), and development of tolerance,¹ which may lead to withdrawal symptoms after discharge. Diphenhydramine, quetiapine, and trazodone are effective as hypnotics through antihistaminergic mechanisms, but efficacy can be compromised by adverse effects mediated by non-histaminergic receptor activity. For example, at doses used for sleep, quetiapine can cause weight gain,² extrapyramidal symptoms, and orthostasis. Trazodone also causes orthostasis and, infrequently, priapism. Because of its relatively high affinity for acetylcholine receptors, diphenhydramine can cause constipation and urinary retention, worsen cognitive function, and exacerbate delirium, particularly in geriatric patients.³

Hydroxyzine is a more selective anti-histamine than the aforementioned molecules,⁴ which leads to the sleep-promoting benefits of Hl-receptor blockade without significant alpha-1 adrenergic antagonism or anticholinergic side effects. The ratio of affinity for H1 receptors to cerebral acetylcholine receptors is more than 10 times greater for hydroxyzine than for diphenhydramine. Similarly, hydroxyzine has greater affinity for H1 receptors than alpha-1 adrenergic receptors, while trazodone has greater affinity for alpha-1 adrenergic receptors than for H1 receptors. Additionally, hydroxyzine does not lead to tolerance.⁵ Finally, it has a potential economic advantage over on-patent drugs such as quetiapine.

A disadvantage to hydroxyzine is its comparatively long half-life of 20 hours. Although this can lead to daytime sedation after nighttime dosing, we have not found this to be clinically significant for most patients.

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Many physicians prescribe hypnotics for hospitalized patients with insomnia. Frequently used medications include temazepam, diphenhydramine, quetiapine, and trazodone. We have found hydroxyzine, 25 mg to 100 mg nightly, to be effective in adults and geriatric patients and feel it is a more rational choice.

Temazepam and other benzodiazepines may cause behavioral disinhibition, delirium (particularly in geriatric patients), and development of tolerance,¹ which may lead to withdrawal symptoms after discharge. Diphenhydramine, quetiapine, and trazodone are effective as hypnotics through antihistaminergic mechanisms, but efficacy can be compromised by adverse effects mediated by non-histaminergic receptor activity. For example, at doses used for sleep, quetiapine can cause weight gain,² extrapyramidal symptoms, and orthostasis. Trazodone also causes orthostasis and, infrequently, priapism. Because of its relatively high affinity for acetylcholine receptors, diphenhydramine can cause constipation and urinary retention, worsen cognitive function, and exacerbate delirium, particularly in geriatric patients.³

Hydroxyzine is a more selective anti-histamine than the aforementioned molecules,⁴ which leads to the sleep-promoting benefits of Hl-receptor blockade without significant alpha-1 adrenergic antagonism or anticholinergic side effects. The ratio of affinity for H1 receptors to cerebral acetylcholine receptors is more than 10 times greater for hydroxyzine than for diphenhydramine. Similarly, hydroxyzine has greater affinity for H1 receptors than alpha-1 adrenergic receptors, while trazodone has greater affinity for alpha-1 adrenergic receptors than for H1 receptors. Additionally, hydroxyzine does not lead to tolerance.⁵ Finally, it has a potential economic advantage over on-patent drugs such as quetiapine.

A disadvantage to hydroxyzine is its comparatively long half-life of 20 hours. Although this can lead to daytime sedation after nighttime dosing, we have not found this to be clinically significant for most patients.

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

The popularity of TV shows such as A&E’s Hoarders,TLC’s Hoarding: buried alive,and Planet Green’s Gutted has increased public awareness of problems caused by hoarding. Seventy-five communities across the United States have coordinated hoarding task forces that include therapists, social workers, police, fire departments, and child protective services, and that number is rising quickly.¹ Therefore, psychiatrists likely will be encountering growing numbers of hoarders and their families seeking treatment.

Hoarding behavior

Affecting 2% to 5% of the population, compulsive hoarding is persistent difficulty parting with possessions—even useless items or those of limited value—that results in cluttered personal surroundings and impaired functioning.² Hoarders may be threatened with eviction or the possibility of losing custody of their children.¹ Hoarding can create fire hazards, fall risks, and unsanitary environments.³

Causes

Hoarding behavior usually is a result of fear of losing items that may be needed later or making the “wrong” decision about what should be kept or discarded.⁴Symptoms generally start at age 12 or 13, begin interfering with daily functioning in the mid-30s, and increase in severity with age.² Clutter can accumulate with or without excessive acquisition of goods, through buying, collecting, or stealing.²Hoarding often is ego-syntonic, and many patients do not believe their behaviors are problematic.³

A new diagnosis?

Hoarding often is associated with obsessive-compulsive disorder (OCD), and DSM-IV-TR lists hoarding behavior as a criterion for obsessive-compulsive personality disorder. However, hoarding behavior has been observed in other neuropsychiatric disorders, including schizophrenia, depression, social phobia, dementia, eating disorders, brain injury, and mental retardation, and in nonclinical populations.^3,4

Most research has focused on the connections between hoarding and OCD, but genetics, brain lesions, neuroimaging, and neuropsychological studies suggest that “hoarding disorder” should be a separate entity in DSM-5.²A proposed set of diagnostic criteria states that the hoarding behavior not be restricted to the symptoms of another mental disorder.² For example, the behavior is not caused by intrusive or recurrent thoughts from OCD or secondary to apathy in depression. The proposed criteria specify if the hoarding is associated with excessive acquisition of items, as well as how much insight the patient has into his or her problem.²

Treatment

Because hoarding behavior frequently is ego-syntonic, patients may be brought in by family members or friends. Treatment should begin with a thorough neuropsychiatric evaluation to determine the etiology of the behavior, such as another axis I disorder.⁴Assess the amount of clutter, types of items saved, usability of living and work spaces, potential health and safety hazards, beliefs about possessions, information processing deficits, avoidance behaviors, insight, motivation for treatment, social and occupational functioning, and activities of daily living.⁴

Studies of selective serotonin reuptake inhibitors and cognitive-behavioral therapy (CBT) in OCD patients with hoarding symptoms have produced mixed results.⁴ In some cases, paroxetine monotherapy, specialized CBT protocols, and combined treatments have proven effective.⁴ Studies examining those treatments’ efficacy for hoarding in the absence of OCD are underway. Whichever strategy is employed, it is important to involve family members or friends in treatment² and to identify other available resources, such as community hoarding task forces.

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

The popularity of TV shows such as A&E’s Hoarders,TLC’s Hoarding: buried alive,and Planet Green’s Gutted has increased public awareness of problems caused by hoarding. Seventy-five communities across the United States have coordinated hoarding task forces that include therapists, social workers, police, fire departments, and child protective services, and that number is rising quickly.¹ Therefore, psychiatrists likely will be encountering growing numbers of hoarders and their families seeking treatment.

Hoarding behavior

Affecting 2% to 5% of the population, compulsive hoarding is persistent difficulty parting with possessions—even useless items or those of limited value—that results in cluttered personal surroundings and impaired functioning.² Hoarders may be threatened with eviction or the possibility of losing custody of their children.¹ Hoarding can create fire hazards, fall risks, and unsanitary environments.³

Causes

Hoarding behavior usually is a result of fear of losing items that may be needed later or making the “wrong” decision about what should be kept or discarded.⁴Symptoms generally start at age 12 or 13, begin interfering with daily functioning in the mid-30s, and increase in severity with age.² Clutter can accumulate with or without excessive acquisition of goods, through buying, collecting, or stealing.²Hoarding often is ego-syntonic, and many patients do not believe their behaviors are problematic.³

A new diagnosis?

Hoarding often is associated with obsessive-compulsive disorder (OCD), and DSM-IV-TR lists hoarding behavior as a criterion for obsessive-compulsive personality disorder. However, hoarding behavior has been observed in other neuropsychiatric disorders, including schizophrenia, depression, social phobia, dementia, eating disorders, brain injury, and mental retardation, and in nonclinical populations.^3,4

Most research has focused on the connections between hoarding and OCD, but genetics, brain lesions, neuroimaging, and neuropsychological studies suggest that “hoarding disorder” should be a separate entity in DSM-5.²A proposed set of diagnostic criteria states that the hoarding behavior not be restricted to the symptoms of another mental disorder.² For example, the behavior is not caused by intrusive or recurrent thoughts from OCD or secondary to apathy in depression. The proposed criteria specify if the hoarding is associated with excessive acquisition of items, as well as how much insight the patient has into his or her problem.²

Treatment

Because hoarding behavior frequently is ego-syntonic, patients may be brought in by family members or friends. Treatment should begin with a thorough neuropsychiatric evaluation to determine the etiology of the behavior, such as another axis I disorder.⁴Assess the amount of clutter, types of items saved, usability of living and work spaces, potential health and safety hazards, beliefs about possessions, information processing deficits, avoidance behaviors, insight, motivation for treatment, social and occupational functioning, and activities of daily living.⁴

Studies of selective serotonin reuptake inhibitors and cognitive-behavioral therapy (CBT) in OCD patients with hoarding symptoms have produced mixed results.⁴ In some cases, paroxetine monotherapy, specialized CBT protocols, and combined treatments have proven effective.⁴ Studies examining those treatments’ efficacy for hoarding in the absence of OCD are underway. Whichever strategy is employed, it is important to involve family members or friends in treatment² and to identify other available resources, such as community hoarding task forces.

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

The popularity of TV shows such as A&E’s Hoarders,TLC’s Hoarding: buried alive,and Planet Green’s Gutted has increased public awareness of problems caused by hoarding. Seventy-five communities across the United States have coordinated hoarding task forces that include therapists, social workers, police, fire departments, and child protective services, and that number is rising quickly.¹ Therefore, psychiatrists likely will be encountering growing numbers of hoarders and their families seeking treatment.

Hoarding behavior

Affecting 2% to 5% of the population, compulsive hoarding is persistent difficulty parting with possessions—even useless items or those of limited value—that results in cluttered personal surroundings and impaired functioning.² Hoarders may be threatened with eviction or the possibility of losing custody of their children.¹ Hoarding can create fire hazards, fall risks, and unsanitary environments.³

Causes

Hoarding behavior usually is a result of fear of losing items that may be needed later or making the “wrong” decision about what should be kept or discarded.⁴Symptoms generally start at age 12 or 13, begin interfering with daily functioning in the mid-30s, and increase in severity with age.² Clutter can accumulate with or without excessive acquisition of goods, through buying, collecting, or stealing.²Hoarding often is ego-syntonic, and many patients do not believe their behaviors are problematic.³

A new diagnosis?

Hoarding often is associated with obsessive-compulsive disorder (OCD), and DSM-IV-TR lists hoarding behavior as a criterion for obsessive-compulsive personality disorder. However, hoarding behavior has been observed in other neuropsychiatric disorders, including schizophrenia, depression, social phobia, dementia, eating disorders, brain injury, and mental retardation, and in nonclinical populations.^3,4

Most research has focused on the connections between hoarding and OCD, but genetics, brain lesions, neuroimaging, and neuropsychological studies suggest that “hoarding disorder” should be a separate entity in DSM-5.²A proposed set of diagnostic criteria states that the hoarding behavior not be restricted to the symptoms of another mental disorder.² For example, the behavior is not caused by intrusive or recurrent thoughts from OCD or secondary to apathy in depression. The proposed criteria specify if the hoarding is associated with excessive acquisition of items, as well as how much insight the patient has into his or her problem.²

Treatment

Because hoarding behavior frequently is ego-syntonic, patients may be brought in by family members or friends. Treatment should begin with a thorough neuropsychiatric evaluation to determine the etiology of the behavior, such as another axis I disorder.⁴Assess the amount of clutter, types of items saved, usability of living and work spaces, potential health and safety hazards, beliefs about possessions, information processing deficits, avoidance behaviors, insight, motivation for treatment, social and occupational functioning, and activities of daily living.⁴

Studies of selective serotonin reuptake inhibitors and cognitive-behavioral therapy (CBT) in OCD patients with hoarding symptoms have produced mixed results.⁴ In some cases, paroxetine monotherapy, specialized CBT protocols, and combined treatments have proven effective.⁴ Studies examining those treatments’ efficacy for hoarding in the absence of OCD are underway. Whichever strategy is employed, it is important to involve family members or friends in treatment² and to identify other available resources, such as community hoarding task forces.

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Dear Dr. Mossman:

Some of my older patients with dementia develop severe behavioral disturbances, and when other treatments don’t work, I sometimes use second-generation antipsychotics (SGAs) to help them cope better. But I worry about the liability I might face because of the “black-box” warning about prescribing SGAs to these patients. How can I minimize the legal risks of doing this?—Submitted by “Dr. K”

“Black-box” warning. The phrase sounds scary, and it’s meant to frighten you—or at least get your attention.

However, the FDA has put boxed warnings on all antidepressants and many other psychotropic drugs. This doesn’t mean you should quit practicing psychopharmacology. Instead, the FDA just wants you to hesitate and be careful when you prescribe certain drugs in certain situations. One such situation is using SGAs to address behavioral problems that often occur in older persons with dementia.

When it comes to prescribing SGAs for patients with dementia, you can respond to your fear of the “black box” with something that isn’t scary at all: doing what’s best for your older patient. In this article, we’ll explain how, as we cover:

• the scope of the clinical problem
• what a “black-box” warning is
• the significance of the boxed warning for SGA use for dementia-related behavioral disturbances
• how to minimize medicolegal liability when prescribing SGAs.

Aging boomers

As the “baby boom” generation enters its 7th and 8th decades, psychiatrists should expect to treat many older individuals who have dementia and behavioral problems. In the United States, approximately 4 million individuals age >60 have dementia,¹ and this number will rise rapidly in the next few years.² Rates of dementia-related agitation and aggression range from 20% to 80%.^3,4 Such behavior—always distressing to patients, family members, and caregivers—can lead to physical injuries, increased caregiver burden, premature institutionalization, physical restraint, and over-medication.

No medication has received FDA approval for treatment of dementia-related agitation. Currently, doctors try a variety of medications, such as memantine, cholinesterase inhibitors, anticonvulsants, and selective serotonin reuptake inhibitors.⁵ Nearly one-third of nursing home residents with dementia receive antipsychotic drugs.⁶ Thus, despite the “black-box” warning, SGAs commonly are prescribed to cognitively impaired older persons for behavioral agitation and/or psychosis.

What’s a ‘black-box’ warning?

Almost every prescription drug has dozens of possible adverse effects. “Black-box” warning is a colloquialism that refers to the FDA’s format for describing particularly important potential complications or precautions necessary when prescribing a drug. (For the official definition of a “boxed warning, “ see Box ).⁷

Box

Understanding the warning

In April 2005, the FDA mandated a boxed warning for SGAs after placebo-controlled studies showed a significantly higher death rate—mostly from cardiovascular accidents or infections—in geriatric patients who received SGA treatment for dementia-related psychoses.⁸ The warning does not forbid you from using SGAs when treating older patients with dementia—but you must think carefully about this off-label treatment (ie, prescribing SGAs for an indication that is not FDA-approved).

In patients with dementia, medical conditions may be expressed as behavioral problems that should be addressed with behavioral therapies or appropriate medical therapy ( Table 1 ).^9,10 You can feel better about starting SGA therapy if a thorough medical, cognitive, and functional workup has ruled out nonpsychiatric reasons for disruptive behavior.^9,11,12 The workup should look for cardiovascular, cerebrovascular, pulmonary, and metabolic risk factors, along with medication side effects.

If medical and situational problems are ruled out, or if aggressive, assaultive, or disruptive behavior threatens the physical safety of patients or others, careful consideration of therapeutic alternatives may show that SGAs are the best treatment choice. Once this decision is reached, clinicians can minimize legal liabilities in several ways.

Table 1

Questions to ask before starting SGAs for dementia-related behavioral problems

Informed consent: A process

Informed consent is an essential feature of most medical treatment ( Table 2 ). ¹³ Informed consent is especially important when—as with using SGAs for behavioral disturbances in dementia—you want to prescribe a drug off-label in a context for which the FDA has required a boxed warning.

Patients in early stages of dementia may retain their decision-making capacity and ability to give informed consent.¹⁴ If the opportunity presents itself, this is an ideal time to discuss the possible future need for SGAs and to make sure the patient has designated a proxy decision-maker who can make treatment choices if the patient loses capacity. If a patient’s decision-making capacity is questionable, obtain consent from a surrogate (often a relative).

Informed consent is a process, not a printed form. It involves taking time to be sure that the patient or surrogate decision-maker understands and accepts the risks associated with a proposed treatment. Thinking of informed consent as a process facilitates communication, acceptance of treatment, and trust between prescribers and recipients of care.

Table 2

Essentials of informed consent

Involving family

When appropriate, include a patient’s family in informed consent and treatment planning processes. Providing written material, such as Treatment of dementia and agitation: a guide for families and caregivers, ¹⁵ can help educate persons whose loved ones suffer from dementia. These resources often improve care and build relationships with family members that sustain treatment alliances when adverse outcomes occur. Also, well-engaged and informed families are less likely to initiate malpractice lawsuits when adverse events occur.¹⁶

Monitor for side effects

Older patients are especially vulnerable to physical harm during agitated or aggressive behavior, but they’re also quite vulnerable to medication side effects. Before starting SGAs, note the patient’s alertness, activities of daily living, movement abnormalities, and EKG abnormalities. Knowing this “baseline” helps you assess the effects of medication and monitor for side effects. Brief assessment scales—such as the Montreal Cognitive Assessment Test,¹⁷ the Abnormal Involuntary Movement Scale,¹⁸ and the Instrumental Activities of Daily Living Scale¹⁹ —can help you quantify baseline functioning, monitor symptom response, and detect adverse effects.

For patients receiving SGA therapy, reassess benefits and risks at least every 3 months, and preferably more often.¹¹ In geriatric patients, titrate dosages slowly, maintain medications at the lowest effective levels, and discontinue them once they are no longer necessary. When doubt arises about the effectiveness of SGA therapy, stop the drug.¹²

Remember to document

Because older patients have high rates of medical problems and medication side effects, negative outcomes always are a risk. Good documentation is a key risk management strategy that can help if a bad outcome requires you to defend your treatment plan in court ( Table 3 ).² ”

Table 3

What to document

Drug Brand Name

• Memantine • Namenda

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Dear Dr. Mossman:

Some of my older patients with dementia develop severe behavioral disturbances, and when other treatments don’t work, I sometimes use second-generation antipsychotics (SGAs) to help them cope better. But I worry about the liability I might face because of the “black-box” warning about prescribing SGAs to these patients. How can I minimize the legal risks of doing this?—Submitted by “Dr. K”

“Black-box” warning. The phrase sounds scary, and it’s meant to frighten you—or at least get your attention.

However, the FDA has put boxed warnings on all antidepressants and many other psychotropic drugs. This doesn’t mean you should quit practicing psychopharmacology. Instead, the FDA just wants you to hesitate and be careful when you prescribe certain drugs in certain situations. One such situation is using SGAs to address behavioral problems that often occur in older persons with dementia.

When it comes to prescribing SGAs for patients with dementia, you can respond to your fear of the “black box” with something that isn’t scary at all: doing what’s best for your older patient. In this article, we’ll explain how, as we cover:

• the scope of the clinical problem
• what a “black-box” warning is
• the significance of the boxed warning for SGA use for dementia-related behavioral disturbances
• how to minimize medicolegal liability when prescribing SGAs.

Aging boomers

As the “baby boom” generation enters its 7th and 8th decades, psychiatrists should expect to treat many older individuals who have dementia and behavioral problems. In the United States, approximately 4 million individuals age >60 have dementia,¹ and this number will rise rapidly in the next few years.² Rates of dementia-related agitation and aggression range from 20% to 80%.^3,4 Such behavior—always distressing to patients, family members, and caregivers—can lead to physical injuries, increased caregiver burden, premature institutionalization, physical restraint, and over-medication.

No medication has received FDA approval for treatment of dementia-related agitation. Currently, doctors try a variety of medications, such as memantine, cholinesterase inhibitors, anticonvulsants, and selective serotonin reuptake inhibitors.⁵ Nearly one-third of nursing home residents with dementia receive antipsychotic drugs.⁶ Thus, despite the “black-box” warning, SGAs commonly are prescribed to cognitively impaired older persons for behavioral agitation and/or psychosis.

What’s a ‘black-box’ warning?

Almost every prescription drug has dozens of possible adverse effects. “Black-box” warning is a colloquialism that refers to the FDA’s format for describing particularly important potential complications or precautions necessary when prescribing a drug. (For the official definition of a “boxed warning, “ see Box ).⁷

Box

Understanding the warning

In April 2005, the FDA mandated a boxed warning for SGAs after placebo-controlled studies showed a significantly higher death rate—mostly from cardiovascular accidents or infections—in geriatric patients who received SGA treatment for dementia-related psychoses.⁸ The warning does not forbid you from using SGAs when treating older patients with dementia—but you must think carefully about this off-label treatment (ie, prescribing SGAs for an indication that is not FDA-approved).

In patients with dementia, medical conditions may be expressed as behavioral problems that should be addressed with behavioral therapies or appropriate medical therapy ( Table 1 ).^9,10 You can feel better about starting SGA therapy if a thorough medical, cognitive, and functional workup has ruled out nonpsychiatric reasons for disruptive behavior.^9,11,12 The workup should look for cardiovascular, cerebrovascular, pulmonary, and metabolic risk factors, along with medication side effects.

If medical and situational problems are ruled out, or if aggressive, assaultive, or disruptive behavior threatens the physical safety of patients or others, careful consideration of therapeutic alternatives may show that SGAs are the best treatment choice. Once this decision is reached, clinicians can minimize legal liabilities in several ways.

Table 1

Questions to ask before starting SGAs for dementia-related behavioral problems

Informed consent: A process

Informed consent is an essential feature of most medical treatment ( Table 2 ). ¹³ Informed consent is especially important when—as with using SGAs for behavioral disturbances in dementia—you want to prescribe a drug off-label in a context for which the FDA has required a boxed warning.

Patients in early stages of dementia may retain their decision-making capacity and ability to give informed consent.¹⁴ If the opportunity presents itself, this is an ideal time to discuss the possible future need for SGAs and to make sure the patient has designated a proxy decision-maker who can make treatment choices if the patient loses capacity. If a patient’s decision-making capacity is questionable, obtain consent from a surrogate (often a relative).

Informed consent is a process, not a printed form. It involves taking time to be sure that the patient or surrogate decision-maker understands and accepts the risks associated with a proposed treatment. Thinking of informed consent as a process facilitates communication, acceptance of treatment, and trust between prescribers and recipients of care.

Table 2

Essentials of informed consent

Involving family

When appropriate, include a patient’s family in informed consent and treatment planning processes. Providing written material, such as Treatment of dementia and agitation: a guide for families and caregivers, ¹⁵ can help educate persons whose loved ones suffer from dementia. These resources often improve care and build relationships with family members that sustain treatment alliances when adverse outcomes occur. Also, well-engaged and informed families are less likely to initiate malpractice lawsuits when adverse events occur.¹⁶

Monitor for side effects

Older patients are especially vulnerable to physical harm during agitated or aggressive behavior, but they’re also quite vulnerable to medication side effects. Before starting SGAs, note the patient’s alertness, activities of daily living, movement abnormalities, and EKG abnormalities. Knowing this “baseline” helps you assess the effects of medication and monitor for side effects. Brief assessment scales—such as the Montreal Cognitive Assessment Test,¹⁷ the Abnormal Involuntary Movement Scale,¹⁸ and the Instrumental Activities of Daily Living Scale¹⁹ —can help you quantify baseline functioning, monitor symptom response, and detect adverse effects.

For patients receiving SGA therapy, reassess benefits and risks at least every 3 months, and preferably more often.¹¹ In geriatric patients, titrate dosages slowly, maintain medications at the lowest effective levels, and discontinue them once they are no longer necessary. When doubt arises about the effectiveness of SGA therapy, stop the drug.¹²

Remember to document

Because older patients have high rates of medical problems and medication side effects, negative outcomes always are a risk. Good documentation is a key risk management strategy that can help if a bad outcome requires you to defend your treatment plan in court ( Table 3 ).² ”

Table 3

What to document

Drug Brand Name

• Memantine • Namenda

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Dear Dr. Mossman:

Some of my older patients with dementia develop severe behavioral disturbances, and when other treatments don’t work, I sometimes use second-generation antipsychotics (SGAs) to help them cope better. But I worry about the liability I might face because of the “black-box” warning about prescribing SGAs to these patients. How can I minimize the legal risks of doing this?—Submitted by “Dr. K”

“Black-box” warning. The phrase sounds scary, and it’s meant to frighten you—or at least get your attention.

However, the FDA has put boxed warnings on all antidepressants and many other psychotropic drugs. This doesn’t mean you should quit practicing psychopharmacology. Instead, the FDA just wants you to hesitate and be careful when you prescribe certain drugs in certain situations. One such situation is using SGAs to address behavioral problems that often occur in older persons with dementia.

When it comes to prescribing SGAs for patients with dementia, you can respond to your fear of the “black box” with something that isn’t scary at all: doing what’s best for your older patient. In this article, we’ll explain how, as we cover:

• the scope of the clinical problem
• what a “black-box” warning is
• the significance of the boxed warning for SGA use for dementia-related behavioral disturbances
• how to minimize medicolegal liability when prescribing SGAs.

Aging boomers

As the “baby boom” generation enters its 7th and 8th decades, psychiatrists should expect to treat many older individuals who have dementia and behavioral problems. In the United States, approximately 4 million individuals age >60 have dementia,¹ and this number will rise rapidly in the next few years.² Rates of dementia-related agitation and aggression range from 20% to 80%.^3,4 Such behavior—always distressing to patients, family members, and caregivers—can lead to physical injuries, increased caregiver burden, premature institutionalization, physical restraint, and over-medication.

No medication has received FDA approval for treatment of dementia-related agitation. Currently, doctors try a variety of medications, such as memantine, cholinesterase inhibitors, anticonvulsants, and selective serotonin reuptake inhibitors.⁵ Nearly one-third of nursing home residents with dementia receive antipsychotic drugs.⁶ Thus, despite the “black-box” warning, SGAs commonly are prescribed to cognitively impaired older persons for behavioral agitation and/or psychosis.

What’s a ‘black-box’ warning?

Almost every prescription drug has dozens of possible adverse effects. “Black-box” warning is a colloquialism that refers to the FDA’s format for describing particularly important potential complications or precautions necessary when prescribing a drug. (For the official definition of a “boxed warning, “ see Box ).⁷

Box

Understanding the warning

In April 2005, the FDA mandated a boxed warning for SGAs after placebo-controlled studies showed a significantly higher death rate—mostly from cardiovascular accidents or infections—in geriatric patients who received SGA treatment for dementia-related psychoses.⁸ The warning does not forbid you from using SGAs when treating older patients with dementia—but you must think carefully about this off-label treatment (ie, prescribing SGAs for an indication that is not FDA-approved).

In patients with dementia, medical conditions may be expressed as behavioral problems that should be addressed with behavioral therapies or appropriate medical therapy ( Table 1 ).^9,10 You can feel better about starting SGA therapy if a thorough medical, cognitive, and functional workup has ruled out nonpsychiatric reasons for disruptive behavior.^9,11,12 The workup should look for cardiovascular, cerebrovascular, pulmonary, and metabolic risk factors, along with medication side effects.

If medical and situational problems are ruled out, or if aggressive, assaultive, or disruptive behavior threatens the physical safety of patients or others, careful consideration of therapeutic alternatives may show that SGAs are the best treatment choice. Once this decision is reached, clinicians can minimize legal liabilities in several ways.

Table 1

Questions to ask before starting SGAs for dementia-related behavioral problems

Informed consent: A process

Informed consent is an essential feature of most medical treatment ( Table 2 ). ¹³ Informed consent is especially important when—as with using SGAs for behavioral disturbances in dementia—you want to prescribe a drug off-label in a context for which the FDA has required a boxed warning.

Patients in early stages of dementia may retain their decision-making capacity and ability to give informed consent.¹⁴ If the opportunity presents itself, this is an ideal time to discuss the possible future need for SGAs and to make sure the patient has designated a proxy decision-maker who can make treatment choices if the patient loses capacity. If a patient’s decision-making capacity is questionable, obtain consent from a surrogate (often a relative).

Informed consent is a process, not a printed form. It involves taking time to be sure that the patient or surrogate decision-maker understands and accepts the risks associated with a proposed treatment. Thinking of informed consent as a process facilitates communication, acceptance of treatment, and trust between prescribers and recipients of care.

Table 2

Essentials of informed consent

Involving family

When appropriate, include a patient’s family in informed consent and treatment planning processes. Providing written material, such as Treatment of dementia and agitation: a guide for families and caregivers, ¹⁵ can help educate persons whose loved ones suffer from dementia. These resources often improve care and build relationships with family members that sustain treatment alliances when adverse outcomes occur. Also, well-engaged and informed families are less likely to initiate malpractice lawsuits when adverse events occur.¹⁶

Monitor for side effects

Older patients are especially vulnerable to physical harm during agitated or aggressive behavior, but they’re also quite vulnerable to medication side effects. Before starting SGAs, note the patient’s alertness, activities of daily living, movement abnormalities, and EKG abnormalities. Knowing this “baseline” helps you assess the effects of medication and monitor for side effects. Brief assessment scales—such as the Montreal Cognitive Assessment Test,¹⁷ the Abnormal Involuntary Movement Scale,¹⁸ and the Instrumental Activities of Daily Living Scale¹⁹ —can help you quantify baseline functioning, monitor symptom response, and detect adverse effects.

For patients receiving SGA therapy, reassess benefits and risks at least every 3 months, and preferably more often.¹¹ In geriatric patients, titrate dosages slowly, maintain medications at the lowest effective levels, and discontinue them once they are no longer necessary. When doubt arises about the effectiveness of SGA therapy, stop the drug.¹²

Remember to document

Because older patients have high rates of medical problems and medication side effects, negative outcomes always are a risk. Good documentation is a key risk management strategy that can help if a bad outcome requires you to defend your treatment plan in court ( Table 3 ).² ”

Table 3

What to document

Drug Brand Name

• Memantine • Namenda

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Discuss this article at http://currentpsychiatry.blogspot.com/2011/03/how-anxiety-presents-differently-in.html#comments

Although anxiety disorders are common at all ages, there is a misconception that their prevalence drastically declines with age. For this reason anxiety disorders often are underdiagnosed and undertreated in geriatric patients, especially when the clinical presentation of these disorders in older patients differs from that seen in younger adults.

In older persons, anxiety symptoms often overlap with medical conditions such as hyperthyroidism and geriatric patients tend to express anxiety symptoms as medical or somatic problems such as pain rather than as psychological distress.¹ As a result, older adults often seek treatment for depressive or anxiety symptoms from their primary care physician instead of a psychiatrist. Unfortunately, primary care physicians often miss psychiatric illness, including anxiety disorders, in geriatric patients.

Anxiety may be a symptom of an underlying psychiatric disturbance, secondary to a general medical condition, or induced by dietary substances, substances of abuse, or medications. Late-life anxiety often is comorbid with major depressive disorder (MDD) ( Box ) and other psychological stressors as older adults recognize declining cognitive and physical functioning.² Anxiety disorders commonly begin in early adulthood, tend to be chronic and interspersed with remissions and relapses, and usually continue into old age.³ In generalized anxiety disorder (GAD), there is a bimodal distribution of onset; approximately two-thirds of patients experience onset between the late teens and late 20s and one-third develop the disorder for the first time after age 50.³

Prevalence rates for anxiety disorders among older adults (age ≥55) range from 3. 5% to 10. 2%.⁴ These rates are slightly lower than those for younger adults.⁵ Among older adults, presence of a 12-month anxiety disorder was associated with female sex, lower education, being unmarried, and having ≥3 or more chronic conditions.⁶

Box

Anxiety and disability risk

Anxiety disorders affect geriatric patients more profoundly than their younger counterparts. Persons age ≥65 who have an anxiety disorder are 3 to 10 times more likely to be hospitalized than younger individuals.¹ Anxiety is associated with high rates of medically unexplained symptoms, increased use of health care resources, chronic medical illness, low levels of physical health-related quality of life, and physical disability.^7,8

Anxiety symptoms may predict progressing physical disability among older women and reduced ability to perform activities of daily living over 1 year.⁹ Anxious geriatric patients are less independent and increase the burden on family and caregivers.¹⁰ Anxiety disorders are associated with lower compliance with medical treatment, which could worsen chronic medical conditions and increase the risk for nursing home admission.¹¹ Anxious older adults report decreased life satisfaction, memory impairment, poorer self perception of health, and increased loneliness.¹²

Generalized anxiety disorder

Although GAD is the most common anxiety disorder among geriatric patients, with a prevalence of 0. 7% to 9%,¹³ it remains underdiagnosed and undertreated.¹⁴ In a cross-sectional observational study of 439 adults age ≥55 with lifetime GAD, approximately one-half experienced onset after age 50.¹⁵ Late onset is associated with more frequent hypertension and a poorer health-related quality of life than early onset.¹⁵

Compared with younger individuals, older persons with GAD have a greater variety of worry topics, including memory loss, medical illnesses, and fear of falls,¹⁶ but worry less about the future and work than younger patients. This type of anxiety is largely situational and temporary, and often accompanies comorbid medical problems (Table 1) .

Obsessive-compulsive disorder

A study comparing older (age ≥60) and younger obsessive-compulsive disorder (OCD) patients found that the clinical presentation of the disorder does not substantially differ between age groups; however, geriatric patients had fewer concerns about symmetry, needing to know, and counting rituals. Handwashing and fear of having sinned were more common.¹⁷

OCD is fairly uncommon in geriatric patients. Prevalence rates decrease with age, ranging between 0% and 0. 8% among persons age ≥60.¹⁸ OCD seldom begins in late life; most geriatric patients with OCD have had symptoms for decades. By late life, most individuals with OCD improve, although they may continue to experience clinical or subclinical symptoms.¹⁹ However, 1 report found a second peak of incidence of OCD in women age ≥65.²⁰ Case reports of late-onset OCD have found evidence of cerebral lesions, often in the basal ganglia, which suggests a possible neurodegenerative pathophysiology.²¹

Table 1

DSM-IV-TR criteria for generalized anxiety disorder

Posttraumatic stress disorder

Untreated posttraumatic stress disorder (PTSD) often is assumed to be a chronic disorder. Recollections of past trauma may lead to new PTSD symptoms in older patients. Neurodegeneration of memory pathways and cognitive impairment associated with Alzheimer‘s disease or vascular or alcohol-related dementia may disinhibit PTSD symptoms in patients whose PTSD was fairly well controlled.²²

Life events associated with aging—death of a spouse, financial and physical decline, chronic pain, or diminished cognitive coping resources—may precipitate or revive PTSD symptoms associated with earlier exposure to severe psychological trauma.²³ These life changes also may precipitate socalled delayed PTSD, when symptoms relating to past traumatic experiences present for the first time. Geriatric patients may be more likely than younger persons to deny their PTSD symptoms if their cultural background emphasizes stoicism and fortitude.²⁴

Phobias

Specific phobias. The prevalence of specific phobias drops dramatically in late life, although older patients might underreport symptoms. Many older persons are afraid of falling. Approximately 60% of older adults with a history of falling—and 30% of older individuals with no such history— report this fear. Fear of falling is more prevalent in women and increases with age.^25,26 This fear may be a protective response to a real threat that prevents older persons from attempting high-risk activities, but it also can cause patients to restrict their activities, which can result in decreased social, physical, or cognitive functioning and loss of in-dependence.²⁵

Social phobias (social anxiety disorder).

Among older adults, common social phobias include eating food around strangers, and—especially in men—being unable to urinate in public bathrooms. In a cross-sectional observational study, social anxiety disorder (SAD) was more common among older persons who reported stressful life events, such as death of a spouse.²⁷ MDD, specific phobia, and personality disorder are associated with SAD in geriatric patients.²⁷ Prevalence rates of SAD appear to slightly decrease with age, although the condition remains common in geriatric patients—5% of older adults report lifetime prevalence—and its presentation is similar to that seen in younger adults.²⁷

Agoraphobia. In older persons the prevalence of agoraphobia is 0. 6%.²⁸ Most cases are of early onset but the condition can present de novo following a stroke or other medical event and can inhibit activities needed for successful rehabilitation. Agoraphobia can present within the context of panic attacks as is seen in younger adults but most geriatric patients with agoraphobia do not have concurrent panic disorder. This phobia is more common in women, widowed or divorced individuals, patients with chronic health conditions, and those with comorbid psychiatric disorders.²⁹

Panic disorder

Panic disorder (PD) rarely starts for the first time after age 60, and most late-onset panic attacks are associated with medical and psychiatric comorbidities. PD tends to be less severe in older individuals than in younger adults.³⁰ Recent stressful life events or losses can predict onset and maintenance of PD. Older patients may present with panic symptoms, such as shortness of breath, dizziness, or trembling, that overlap with age-related medical conditions. PD may be prevalent in older patients with chest pain and no evidence of coronary artery disease.³¹ Panic symptoms that are secondary to underlying medical conditions, such as chronic obstructive pulmonary disease exacerbation, usually wax and wane.³²

Treatment

Treatment for anxiety disorders in geriatric patients may involve a combination of psychotherapy, pharmacotherapy, and complementary and alternative therapies. Treatment may be complicated if patients have ≥1 anxiety disorder or suffer from comorbid depression, substance abuse, or medical problems. As is seen with younger adults, the course of anxiety disorders in older patients waxes and wanes, but most disorders are unlikely to remit completely.³³ Aging may influence the effects of psychotropic medications in older patients. Increased distribution and decreased metabolism and clearance of medications results in higher medication plasma levels and longer elimination half-lives. Medication compliance in older patients may be complicated by:

• older patients’ sensitivity to anticho-linergic side effects
• coexisting medical illnesses
• polypharmacy, particularly in institutionalized settings
• sensory and cognitive deficits.³⁴

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) generally are safe and produce fewer side effects compared with tricyclic antidepressants (TCAs), especially in geriatric patients. SSRIs and SNRIs may be useful for GAD, PD, OCD, and PTSD in older patients.³⁵ TCAs can effectively treat anxiety symptoms but may be cardiotoxic and their anticholinergic properties can lead to serious side effects. Benzodiazepines often are used for acute or short-term anxiety management, but chronic use in geriatric patients can cause cognitive impairment, falls, and other serious side effects. Buspirone may be beneficial for GAD but is not effective for PD.³⁶ The drug is well tolerated in older persons, but may take 2 to 4 weeks to be effective ( Table 2 ).³⁵

Pharmacotherapy for anxiety disorders in geriatric patients often is used in conjunction with psychotherapy. Psychotherapeutic approaches include cognitive-behavioral therapy (CBT), exposure therapy, dialectical behavioral therapy, and interpersonal therapy. Increasing evidence supports the effectiveness of psychotherapy in treating anxiety disorders in younger adults as well as in older patients, often in combination with pharmacotherapy.³⁷ In older patients with GAD, CBT is associated with a greater improvement in worry severity, depressive symptoms, and overall mental health compared with usual care.³⁸

In addition to traditional pharmacotherapy, complementary and alternative therapies often are used for late-life anxiety. These therapies include biofeedback, progressive relaxation, acupuncture, yoga, massage therapy, art, music, or dance therapy, meditation, prayer, and spiritual counseling.

Table 2

Pharmacotherapy for anxiety disorders in older adults

Related Resources

• Wetherell JL, Lenze EJ, Stanley MA. Evidence-based treatment of geriatric anxiety disorders. Psychiatr Clin North Am. 2005; 28(4): 871-896, ix.
• Lenze EJ, Wetherell JL. Anxiety disorders. In: Blazer DG, Steffens DC, eds. The American Psychiatric Publishing textbook of geriatric psychiatry. Arlington, VA: American Psychiatric Publishing, Inc; 2009: 333-345.

Drug Brand Name

• Buspirone • BuSpar

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article, or with manufacturers of competing products.

Discuss this article at http://currentpsychiatry.blogspot.com/2011/03/how-anxiety-presents-differently-in.html#comments

Although anxiety disorders are common at all ages, there is a misconception that their prevalence drastically declines with age. For this reason anxiety disorders often are underdiagnosed and undertreated in geriatric patients, especially when the clinical presentation of these disorders in older patients differs from that seen in younger adults.

In older persons, anxiety symptoms often overlap with medical conditions such as hyperthyroidism and geriatric patients tend to express anxiety symptoms as medical or somatic problems such as pain rather than as psychological distress.¹ As a result, older adults often seek treatment for depressive or anxiety symptoms from their primary care physician instead of a psychiatrist. Unfortunately, primary care physicians often miss psychiatric illness, including anxiety disorders, in geriatric patients.

Anxiety may be a symptom of an underlying psychiatric disturbance, secondary to a general medical condition, or induced by dietary substances, substances of abuse, or medications. Late-life anxiety often is comorbid with major depressive disorder (MDD) ( Box ) and other psychological stressors as older adults recognize declining cognitive and physical functioning.² Anxiety disorders commonly begin in early adulthood, tend to be chronic and interspersed with remissions and relapses, and usually continue into old age.³ In generalized anxiety disorder (GAD), there is a bimodal distribution of onset; approximately two-thirds of patients experience onset between the late teens and late 20s and one-third develop the disorder for the first time after age 50.³

Prevalence rates for anxiety disorders among older adults (age ≥55) range from 3. 5% to 10. 2%.⁴ These rates are slightly lower than those for younger adults.⁵ Among older adults, presence of a 12-month anxiety disorder was associated with female sex, lower education, being unmarried, and having ≥3 or more chronic conditions.⁶

Box

Anxiety and disability risk

Anxiety disorders affect geriatric patients more profoundly than their younger counterparts. Persons age ≥65 who have an anxiety disorder are 3 to 10 times more likely to be hospitalized than younger individuals.¹ Anxiety is associated with high rates of medically unexplained symptoms, increased use of health care resources, chronic medical illness, low levels of physical health-related quality of life, and physical disability.^7,8

Anxiety symptoms may predict progressing physical disability among older women and reduced ability to perform activities of daily living over 1 year.⁹ Anxious geriatric patients are less independent and increase the burden on family and caregivers.¹⁰ Anxiety disorders are associated with lower compliance with medical treatment, which could worsen chronic medical conditions and increase the risk for nursing home admission.¹¹ Anxious older adults report decreased life satisfaction, memory impairment, poorer self perception of health, and increased loneliness.¹²

Generalized anxiety disorder

Although GAD is the most common anxiety disorder among geriatric patients, with a prevalence of 0. 7% to 9%,¹³ it remains underdiagnosed and undertreated.¹⁴ In a cross-sectional observational study of 439 adults age ≥55 with lifetime GAD, approximately one-half experienced onset after age 50.¹⁵ Late onset is associated with more frequent hypertension and a poorer health-related quality of life than early onset.¹⁵

Compared with younger individuals, older persons with GAD have a greater variety of worry topics, including memory loss, medical illnesses, and fear of falls,¹⁶ but worry less about the future and work than younger patients. This type of anxiety is largely situational and temporary, and often accompanies comorbid medical problems (Table 1) .

Obsessive-compulsive disorder

A study comparing older (age ≥60) and younger obsessive-compulsive disorder (OCD) patients found that the clinical presentation of the disorder does not substantially differ between age groups; however, geriatric patients had fewer concerns about symmetry, needing to know, and counting rituals. Handwashing and fear of having sinned were more common.¹⁷

OCD is fairly uncommon in geriatric patients. Prevalence rates decrease with age, ranging between 0% and 0. 8% among persons age ≥60.¹⁸ OCD seldom begins in late life; most geriatric patients with OCD have had symptoms for decades. By late life, most individuals with OCD improve, although they may continue to experience clinical or subclinical symptoms.¹⁹ However, 1 report found a second peak of incidence of OCD in women age ≥65.²⁰ Case reports of late-onset OCD have found evidence of cerebral lesions, often in the basal ganglia, which suggests a possible neurodegenerative pathophysiology.²¹

Table 1

DSM-IV-TR criteria for generalized anxiety disorder

Posttraumatic stress disorder

Untreated posttraumatic stress disorder (PTSD) often is assumed to be a chronic disorder. Recollections of past trauma may lead to new PTSD symptoms in older patients. Neurodegeneration of memory pathways and cognitive impairment associated with Alzheimer‘s disease or vascular or alcohol-related dementia may disinhibit PTSD symptoms in patients whose PTSD was fairly well controlled.²²

Life events associated with aging—death of a spouse, financial and physical decline, chronic pain, or diminished cognitive coping resources—may precipitate or revive PTSD symptoms associated with earlier exposure to severe psychological trauma.²³ These life changes also may precipitate socalled delayed PTSD, when symptoms relating to past traumatic experiences present for the first time. Geriatric patients may be more likely than younger persons to deny their PTSD symptoms if their cultural background emphasizes stoicism and fortitude.²⁴

Phobias

Specific phobias. The prevalence of specific phobias drops dramatically in late life, although older patients might underreport symptoms. Many older persons are afraid of falling. Approximately 60% of older adults with a history of falling—and 30% of older individuals with no such history— report this fear. Fear of falling is more prevalent in women and increases with age.^25,26 This fear may be a protective response to a real threat that prevents older persons from attempting high-risk activities, but it also can cause patients to restrict their activities, which can result in decreased social, physical, or cognitive functioning and loss of in-dependence.²⁵

Social phobias (social anxiety disorder).

Among older adults, common social phobias include eating food around strangers, and—especially in men—being unable to urinate in public bathrooms. In a cross-sectional observational study, social anxiety disorder (SAD) was more common among older persons who reported stressful life events, such as death of a spouse.²⁷ MDD, specific phobia, and personality disorder are associated with SAD in geriatric patients.²⁷ Prevalence rates of SAD appear to slightly decrease with age, although the condition remains common in geriatric patients—5% of older adults report lifetime prevalence—and its presentation is similar to that seen in younger adults.²⁷

Agoraphobia. In older persons the prevalence of agoraphobia is 0. 6%.²⁸ Most cases are of early onset but the condition can present de novo following a stroke or other medical event and can inhibit activities needed for successful rehabilitation. Agoraphobia can present within the context of panic attacks as is seen in younger adults but most geriatric patients with agoraphobia do not have concurrent panic disorder. This phobia is more common in women, widowed or divorced individuals, patients with chronic health conditions, and those with comorbid psychiatric disorders.²⁹

Panic disorder

Panic disorder (PD) rarely starts for the first time after age 60, and most late-onset panic attacks are associated with medical and psychiatric comorbidities. PD tends to be less severe in older individuals than in younger adults.³⁰ Recent stressful life events or losses can predict onset and maintenance of PD. Older patients may present with panic symptoms, such as shortness of breath, dizziness, or trembling, that overlap with age-related medical conditions. PD may be prevalent in older patients with chest pain and no evidence of coronary artery disease.³¹ Panic symptoms that are secondary to underlying medical conditions, such as chronic obstructive pulmonary disease exacerbation, usually wax and wane.³²

Treatment

Treatment for anxiety disorders in geriatric patients may involve a combination of psychotherapy, pharmacotherapy, and complementary and alternative therapies. Treatment may be complicated if patients have ≥1 anxiety disorder or suffer from comorbid depression, substance abuse, or medical problems. As is seen with younger adults, the course of anxiety disorders in older patients waxes and wanes, but most disorders are unlikely to remit completely.³³ Aging may influence the effects of psychotropic medications in older patients. Increased distribution and decreased metabolism and clearance of medications results in higher medication plasma levels and longer elimination half-lives. Medication compliance in older patients may be complicated by:

• older patients’ sensitivity to anticho-linergic side effects
• coexisting medical illnesses
• polypharmacy, particularly in institutionalized settings
• sensory and cognitive deficits.³⁴

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) generally are safe and produce fewer side effects compared with tricyclic antidepressants (TCAs), especially in geriatric patients. SSRIs and SNRIs may be useful for GAD, PD, OCD, and PTSD in older patients.³⁵ TCAs can effectively treat anxiety symptoms but may be cardiotoxic and their anticholinergic properties can lead to serious side effects. Benzodiazepines often are used for acute or short-term anxiety management, but chronic use in geriatric patients can cause cognitive impairment, falls, and other serious side effects. Buspirone may be beneficial for GAD but is not effective for PD.³⁶ The drug is well tolerated in older persons, but may take 2 to 4 weeks to be effective ( Table 2 ).³⁵

Pharmacotherapy for anxiety disorders in geriatric patients often is used in conjunction with psychotherapy. Psychotherapeutic approaches include cognitive-behavioral therapy (CBT), exposure therapy, dialectical behavioral therapy, and interpersonal therapy. Increasing evidence supports the effectiveness of psychotherapy in treating anxiety disorders in younger adults as well as in older patients, often in combination with pharmacotherapy.³⁷ In older patients with GAD, CBT is associated with a greater improvement in worry severity, depressive symptoms, and overall mental health compared with usual care.³⁸

In addition to traditional pharmacotherapy, complementary and alternative therapies often are used for late-life anxiety. These therapies include biofeedback, progressive relaxation, acupuncture, yoga, massage therapy, art, music, or dance therapy, meditation, prayer, and spiritual counseling.

Table 2

Pharmacotherapy for anxiety disorders in older adults

Related Resources

• Wetherell JL, Lenze EJ, Stanley MA. Evidence-based treatment of geriatric anxiety disorders. Psychiatr Clin North Am. 2005; 28(4): 871-896, ix.
• Lenze EJ, Wetherell JL. Anxiety disorders. In: Blazer DG, Steffens DC, eds. The American Psychiatric Publishing textbook of geriatric psychiatry. Arlington, VA: American Psychiatric Publishing, Inc; 2009: 333-345.

Drug Brand Name

• Buspirone • BuSpar

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article, or with manufacturers of competing products.

Discuss this article at http://currentpsychiatry.blogspot.com/2011/03/how-anxiety-presents-differently-in.html#comments

Although anxiety disorders are common at all ages, there is a misconception that their prevalence drastically declines with age. For this reason anxiety disorders often are underdiagnosed and undertreated in geriatric patients, especially when the clinical presentation of these disorders in older patients differs from that seen in younger adults.

In older persons, anxiety symptoms often overlap with medical conditions such as hyperthyroidism and geriatric patients tend to express anxiety symptoms as medical or somatic problems such as pain rather than as psychological distress.¹ As a result, older adults often seek treatment for depressive or anxiety symptoms from their primary care physician instead of a psychiatrist. Unfortunately, primary care physicians often miss psychiatric illness, including anxiety disorders, in geriatric patients.

Anxiety may be a symptom of an underlying psychiatric disturbance, secondary to a general medical condition, or induced by dietary substances, substances of abuse, or medications. Late-life anxiety often is comorbid with major depressive disorder (MDD) ( Box ) and other psychological stressors as older adults recognize declining cognitive and physical functioning.² Anxiety disorders commonly begin in early adulthood, tend to be chronic and interspersed with remissions and relapses, and usually continue into old age.³ In generalized anxiety disorder (GAD), there is a bimodal distribution of onset; approximately two-thirds of patients experience onset between the late teens and late 20s and one-third develop the disorder for the first time after age 50.³

Prevalence rates for anxiety disorders among older adults (age ≥55) range from 3. 5% to 10. 2%.⁴ These rates are slightly lower than those for younger adults.⁵ Among older adults, presence of a 12-month anxiety disorder was associated with female sex, lower education, being unmarried, and having ≥3 or more chronic conditions.⁶

Box

Anxiety and disability risk

Anxiety disorders affect geriatric patients more profoundly than their younger counterparts. Persons age ≥65 who have an anxiety disorder are 3 to 10 times more likely to be hospitalized than younger individuals.¹ Anxiety is associated with high rates of medically unexplained symptoms, increased use of health care resources, chronic medical illness, low levels of physical health-related quality of life, and physical disability.^7,8

Anxiety symptoms may predict progressing physical disability among older women and reduced ability to perform activities of daily living over 1 year.⁹ Anxious geriatric patients are less independent and increase the burden on family and caregivers.¹⁰ Anxiety disorders are associated with lower compliance with medical treatment, which could worsen chronic medical conditions and increase the risk for nursing home admission.¹¹ Anxious older adults report decreased life satisfaction, memory impairment, poorer self perception of health, and increased loneliness.¹²

Generalized anxiety disorder

Although GAD is the most common anxiety disorder among geriatric patients, with a prevalence of 0. 7% to 9%,¹³ it remains underdiagnosed and undertreated.¹⁴ In a cross-sectional observational study of 439 adults age ≥55 with lifetime GAD, approximately one-half experienced onset after age 50.¹⁵ Late onset is associated with more frequent hypertension and a poorer health-related quality of life than early onset.¹⁵

Compared with younger individuals, older persons with GAD have a greater variety of worry topics, including memory loss, medical illnesses, and fear of falls,¹⁶ but worry less about the future and work than younger patients. This type of anxiety is largely situational and temporary, and often accompanies comorbid medical problems (Table 1) .

Obsessive-compulsive disorder

A study comparing older (age ≥60) and younger obsessive-compulsive disorder (OCD) patients found that the clinical presentation of the disorder does not substantially differ between age groups; however, geriatric patients had fewer concerns about symmetry, needing to know, and counting rituals. Handwashing and fear of having sinned were more common.¹⁷

OCD is fairly uncommon in geriatric patients. Prevalence rates decrease with age, ranging between 0% and 0. 8% among persons age ≥60.¹⁸ OCD seldom begins in late life; most geriatric patients with OCD have had symptoms for decades. By late life, most individuals with OCD improve, although they may continue to experience clinical or subclinical symptoms.¹⁹ However, 1 report found a second peak of incidence of OCD in women age ≥65.²⁰ Case reports of late-onset OCD have found evidence of cerebral lesions, often in the basal ganglia, which suggests a possible neurodegenerative pathophysiology.²¹

Table 1

DSM-IV-TR criteria for generalized anxiety disorder

Posttraumatic stress disorder

Untreated posttraumatic stress disorder (PTSD) often is assumed to be a chronic disorder. Recollections of past trauma may lead to new PTSD symptoms in older patients. Neurodegeneration of memory pathways and cognitive impairment associated with Alzheimer‘s disease or vascular or alcohol-related dementia may disinhibit PTSD symptoms in patients whose PTSD was fairly well controlled.²²

Life events associated with aging—death of a spouse, financial and physical decline, chronic pain, or diminished cognitive coping resources—may precipitate or revive PTSD symptoms associated with earlier exposure to severe psychological trauma.²³ These life changes also may precipitate socalled delayed PTSD, when symptoms relating to past traumatic experiences present for the first time. Geriatric patients may be more likely than younger persons to deny their PTSD symptoms if their cultural background emphasizes stoicism and fortitude.²⁴

Phobias

Specific phobias. The prevalence of specific phobias drops dramatically in late life, although older patients might underreport symptoms. Many older persons are afraid of falling. Approximately 60% of older adults with a history of falling—and 30% of older individuals with no such history— report this fear. Fear of falling is more prevalent in women and increases with age.^25,26 This fear may be a protective response to a real threat that prevents older persons from attempting high-risk activities, but it also can cause patients to restrict their activities, which can result in decreased social, physical, or cognitive functioning and loss of in-dependence.²⁵

Social phobias (social anxiety disorder).

Among older adults, common social phobias include eating food around strangers, and—especially in men—being unable to urinate in public bathrooms. In a cross-sectional observational study, social anxiety disorder (SAD) was more common among older persons who reported stressful life events, such as death of a spouse.²⁷ MDD, specific phobia, and personality disorder are associated with SAD in geriatric patients.²⁷ Prevalence rates of SAD appear to slightly decrease with age, although the condition remains common in geriatric patients—5% of older adults report lifetime prevalence—and its presentation is similar to that seen in younger adults.²⁷

Agoraphobia. In older persons the prevalence of agoraphobia is 0. 6%.²⁸ Most cases are of early onset but the condition can present de novo following a stroke or other medical event and can inhibit activities needed for successful rehabilitation. Agoraphobia can present within the context of panic attacks as is seen in younger adults but most geriatric patients with agoraphobia do not have concurrent panic disorder. This phobia is more common in women, widowed or divorced individuals, patients with chronic health conditions, and those with comorbid psychiatric disorders.²⁹

Panic disorder

Panic disorder (PD) rarely starts for the first time after age 60, and most late-onset panic attacks are associated with medical and psychiatric comorbidities. PD tends to be less severe in older individuals than in younger adults.³⁰ Recent stressful life events or losses can predict onset and maintenance of PD. Older patients may present with panic symptoms, such as shortness of breath, dizziness, or trembling, that overlap with age-related medical conditions. PD may be prevalent in older patients with chest pain and no evidence of coronary artery disease.³¹ Panic symptoms that are secondary to underlying medical conditions, such as chronic obstructive pulmonary disease exacerbation, usually wax and wane.³²

Treatment

Treatment for anxiety disorders in geriatric patients may involve a combination of psychotherapy, pharmacotherapy, and complementary and alternative therapies. Treatment may be complicated if patients have ≥1 anxiety disorder or suffer from comorbid depression, substance abuse, or medical problems. As is seen with younger adults, the course of anxiety disorders in older patients waxes and wanes, but most disorders are unlikely to remit completely.³³ Aging may influence the effects of psychotropic medications in older patients. Increased distribution and decreased metabolism and clearance of medications results in higher medication plasma levels and longer elimination half-lives. Medication compliance in older patients may be complicated by:

• older patients’ sensitivity to anticho-linergic side effects
• coexisting medical illnesses
• polypharmacy, particularly in institutionalized settings
• sensory and cognitive deficits.³⁴

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) generally are safe and produce fewer side effects compared with tricyclic antidepressants (TCAs), especially in geriatric patients. SSRIs and SNRIs may be useful for GAD, PD, OCD, and PTSD in older patients.³⁵ TCAs can effectively treat anxiety symptoms but may be cardiotoxic and their anticholinergic properties can lead to serious side effects. Benzodiazepines often are used for acute or short-term anxiety management, but chronic use in geriatric patients can cause cognitive impairment, falls, and other serious side effects. Buspirone may be beneficial for GAD but is not effective for PD.³⁶ The drug is well tolerated in older persons, but may take 2 to 4 weeks to be effective ( Table 2 ).³⁵

Pharmacotherapy for anxiety disorders in geriatric patients often is used in conjunction with psychotherapy. Psychotherapeutic approaches include cognitive-behavioral therapy (CBT), exposure therapy, dialectical behavioral therapy, and interpersonal therapy. Increasing evidence supports the effectiveness of psychotherapy in treating anxiety disorders in younger adults as well as in older patients, often in combination with pharmacotherapy.³⁷ In older patients with GAD, CBT is associated with a greater improvement in worry severity, depressive symptoms, and overall mental health compared with usual care.³⁸

In addition to traditional pharmacotherapy, complementary and alternative therapies often are used for late-life anxiety. These therapies include biofeedback, progressive relaxation, acupuncture, yoga, massage therapy, art, music, or dance therapy, meditation, prayer, and spiritual counseling.

Table 2

Pharmacotherapy for anxiety disorders in older adults

Related Resources

• Wetherell JL, Lenze EJ, Stanley MA. Evidence-based treatment of geriatric anxiety disorders. Psychiatr Clin North Am. 2005; 28(4): 871-896, ix.
• Lenze EJ, Wetherell JL. Anxiety disorders. In: Blazer DG, Steffens DC, eds. The American Psychiatric Publishing textbook of geriatric psychiatry. Arlington, VA: American Psychiatric Publishing, Inc; 2009: 333-345.

Drug Brand Name

• Buspirone • BuSpar

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article, or with manufacturers of competing products.

A recent analysis of the ICD Registry from the National Cardiovascular Data Registry raises significant concerns about the effectiveness of the treatment guidelines for implantable cardioverter defibrillators for the primary prevention of sudden cardiac arrhythmic death.

That study indicates that, although the guidelines as proposed by the sponsoring societies were adhered to in most implantations, a disappointing one-quarter of the implantations were outside of the guidelines. Of the over 111,707 ICDs implanted between 2006 and 2009, 25,145 (22.5%) were implanted in patients who were outside of the recommended guidelines. Certainly one can make a case for the fact that these are only guidelines, and doctor should have the prerogative to make clinical decisions, but there have been few guidelines that have been as carefully explored as those for ICD implantation. They emphasize not only the benefit of the devices implanted within the guidelines, but the hazards of the implantation outside of the guidelines (JAMA 2011;305:43-9).

Four guideline deviations were identified and included implantation carried out within 40 days of an acute MI, in 37%; within 3 months of coronary artery bypass surgery, in 3%; in patients with New York Heart Association class IV symptoms, in 12%; and in newly diagnosed heart failure, in 62%. There are adequate randomized clinical trials that clearly show the lack of benefit or increased risks of implantation in these four classes of patients.

Both the cardiology community and the device manufacturers have emphasized the importance of ICD therapy in as many individuals who fit the criteria for implantation as possible. Despite this effort, the implantation of ICDs on the potential candidates with systolic heart failure has significantly lagged. These results may have a further cooling effect on the rate of future implantation.

There are adequate randomized clinical trials that clearly demonstrate the lack of benefit or increased risks of implantation in these four classes of heart failure patients. The delay in implantation in new heart failure patients has been dictated by the observations that many individuals improve cardiac function after an acute event. In addition, a number of studies have shown that implantation at time of surgery is without merit and with some risk, and we have learned that the mode of death in NYHA class IV patients is dominated by progressive heart failure and not primary arrhythmias.

The use of ICDs within 40 days of an acute MI is of particular importance. Several studies have raised concern about the increase in heart failure mortality in patients who have experienced both appropriate and inappropriate ICD discharge for arrhythmias. It is unclear whether the increased heart failure precedes or is a result of ICD discharge. Similar observations were made in patients in whom an ICD was implanted early after an acute MI for the primary prevention of arrhythmic deaths. A recent study of the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT) re-examines the observation that that heart failure mortality increased in patients who received an ICD shock (Circulation 2010;122:2645-52). DINAMIT enrolled patients 6–40 days after an acute MI in patients with left ventricular ejection fraction of less than 35%. Although ICD therapy decreased arrhythmic deaths, there was an increase in heart failure mortality in those patients who had an ICD shock, which resulted in a net increased mortality.

Both the American College of Cardiology and the Heart Rhythm Society have expressed concern about the recent report and plan to further emphasize ICD guidelines. The HRS is cooperating with the Department of Justice in an investigation of the inappropriate Medicare payments of ICDs “to lend expertise concerning the proper guidelines for clinical decision making,” according to a statement. Should the Justice Department become involved in the appropriate use of medical guidelines, an entirely new disturbing dimension would be introduced in regard to guideline application. In the meantime, both cardiologists and noncardiologists should rethink their decisions in regard to the use of ICDs. They clearly represent an important medical advance that has saved the lives of many of our patients, but their use does have significant risks which must be balanced against their benefit.

A recent analysis of the ICD Registry from the National Cardiovascular Data Registry raises significant concerns about the effectiveness of the treatment guidelines for implantable cardioverter defibrillators for the primary prevention of sudden cardiac arrhythmic death.

That study indicates that, although the guidelines as proposed by the sponsoring societies were adhered to in most implantations, a disappointing one-quarter of the implantations were outside of the guidelines. Of the over 111,707 ICDs implanted between 2006 and 2009, 25,145 (22.5%) were implanted in patients who were outside of the recommended guidelines. Certainly one can make a case for the fact that these are only guidelines, and doctor should have the prerogative to make clinical decisions, but there have been few guidelines that have been as carefully explored as those for ICD implantation. They emphasize not only the benefit of the devices implanted within the guidelines, but the hazards of the implantation outside of the guidelines (JAMA 2011;305:43-9).

Four guideline deviations were identified and included implantation carried out within 40 days of an acute MI, in 37%; within 3 months of coronary artery bypass surgery, in 3%; in patients with New York Heart Association class IV symptoms, in 12%; and in newly diagnosed heart failure, in 62%. There are adequate randomized clinical trials that clearly show the lack of benefit or increased risks of implantation in these four classes of patients.

Both the cardiology community and the device manufacturers have emphasized the importance of ICD therapy in as many individuals who fit the criteria for implantation as possible. Despite this effort, the implantation of ICDs on the potential candidates with systolic heart failure has significantly lagged. These results may have a further cooling effect on the rate of future implantation.

There are adequate randomized clinical trials that clearly demonstrate the lack of benefit or increased risks of implantation in these four classes of heart failure patients. The delay in implantation in new heart failure patients has been dictated by the observations that many individuals improve cardiac function after an acute event. In addition, a number of studies have shown that implantation at time of surgery is without merit and with some risk, and we have learned that the mode of death in NYHA class IV patients is dominated by progressive heart failure and not primary arrhythmias.

The use of ICDs within 40 days of an acute MI is of particular importance. Several studies have raised concern about the increase in heart failure mortality in patients who have experienced both appropriate and inappropriate ICD discharge for arrhythmias. It is unclear whether the increased heart failure precedes or is a result of ICD discharge. Similar observations were made in patients in whom an ICD was implanted early after an acute MI for the primary prevention of arrhythmic deaths. A recent study of the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT) re-examines the observation that that heart failure mortality increased in patients who received an ICD shock (Circulation 2010;122:2645-52). DINAMIT enrolled patients 6–40 days after an acute MI in patients with left ventricular ejection fraction of less than 35%. Although ICD therapy decreased arrhythmic deaths, there was an increase in heart failure mortality in those patients who had an ICD shock, which resulted in a net increased mortality.

Both the American College of Cardiology and the Heart Rhythm Society have expressed concern about the recent report and plan to further emphasize ICD guidelines. The HRS is cooperating with the Department of Justice in an investigation of the inappropriate Medicare payments of ICDs “to lend expertise concerning the proper guidelines for clinical decision making,” according to a statement. Should the Justice Department become involved in the appropriate use of medical guidelines, an entirely new disturbing dimension would be introduced in regard to guideline application. In the meantime, both cardiologists and noncardiologists should rethink their decisions in regard to the use of ICDs. They clearly represent an important medical advance that has saved the lives of many of our patients, but their use does have significant risks which must be balanced against their benefit.

A recent analysis of the ICD Registry from the National Cardiovascular Data Registry raises significant concerns about the effectiveness of the treatment guidelines for implantable cardioverter defibrillators for the primary prevention of sudden cardiac arrhythmic death.

That study indicates that, although the guidelines as proposed by the sponsoring societies were adhered to in most implantations, a disappointing one-quarter of the implantations were outside of the guidelines. Of the over 111,707 ICDs implanted between 2006 and 2009, 25,145 (22.5%) were implanted in patients who were outside of the recommended guidelines. Certainly one can make a case for the fact that these are only guidelines, and doctor should have the prerogative to make clinical decisions, but there have been few guidelines that have been as carefully explored as those for ICD implantation. They emphasize not only the benefit of the devices implanted within the guidelines, but the hazards of the implantation outside of the guidelines (JAMA 2011;305:43-9).

Four guideline deviations were identified and included implantation carried out within 40 days of an acute MI, in 37%; within 3 months of coronary artery bypass surgery, in 3%; in patients with New York Heart Association class IV symptoms, in 12%; and in newly diagnosed heart failure, in 62%. There are adequate randomized clinical trials that clearly show the lack of benefit or increased risks of implantation in these four classes of patients.

Both the cardiology community and the device manufacturers have emphasized the importance of ICD therapy in as many individuals who fit the criteria for implantation as possible. Despite this effort, the implantation of ICDs on the potential candidates with systolic heart failure has significantly lagged. These results may have a further cooling effect on the rate of future implantation.

There are adequate randomized clinical trials that clearly demonstrate the lack of benefit or increased risks of implantation in these four classes of heart failure patients. The delay in implantation in new heart failure patients has been dictated by the observations that many individuals improve cardiac function after an acute event. In addition, a number of studies have shown that implantation at time of surgery is without merit and with some risk, and we have learned that the mode of death in NYHA class IV patients is dominated by progressive heart failure and not primary arrhythmias.

The use of ICDs within 40 days of an acute MI is of particular importance. Several studies have raised concern about the increase in heart failure mortality in patients who have experienced both appropriate and inappropriate ICD discharge for arrhythmias. It is unclear whether the increased heart failure precedes or is a result of ICD discharge. Similar observations were made in patients in whom an ICD was implanted early after an acute MI for the primary prevention of arrhythmic deaths. A recent study of the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT) re-examines the observation that that heart failure mortality increased in patients who received an ICD shock (Circulation 2010;122:2645-52). DINAMIT enrolled patients 6–40 days after an acute MI in patients with left ventricular ejection fraction of less than 35%. Although ICD therapy decreased arrhythmic deaths, there was an increase in heart failure mortality in those patients who had an ICD shock, which resulted in a net increased mortality.

Both the American College of Cardiology and the Heart Rhythm Society have expressed concern about the recent report and plan to further emphasize ICD guidelines. The HRS is cooperating with the Department of Justice in an investigation of the inappropriate Medicare payments of ICDs “to lend expertise concerning the proper guidelines for clinical decision making,” according to a statement. Should the Justice Department become involved in the appropriate use of medical guidelines, an entirely new disturbing dimension would be introduced in regard to guideline application. In the meantime, both cardiologists and noncardiologists should rethink their decisions in regard to the use of ICDs. They clearly represent an important medical advance that has saved the lives of many of our patients, but their use does have significant risks which must be balanced against their benefit.

It is important for pediatricians to recommend that their female patients seek gynecologic care by age 18 years at the latest. However, there is a role for gynecologic care as early as age 14 or 15 years in this patient population if a teenager is sexually active, is considering becoming sexually active, or has problems with her menstrual period.

Make it a policy to take the gynecologic history with the patient without the parent being present, starting at the age of 14 years or earlier, on an individualized basis. Asking the parent to leave the room as a part of routine practice makes this discussion far easier.

Start your consultation by asking specific questions about the girl's menstrual period. Oftentimes, their periods are irregular, painful, or heavier/longer than they think is normal. If this is the case, it is appropriate to refer your patient to a gynecologist. Also refer your patient if she expresses an interest in seeing a gynecologist for any reason.

Ask about boyfriends, sexual activity, and birth control. Often, girls do not want their parents to know about their sexual activity. I recommend you tell parents that you routinely recommend referral to a gynecologist at a certain age to address menstrual issues. This is an easy way to bring up the subject without making the patient or parent feel uncomfortable.

As a general pediatrician, you can manage this type of patient if you feel comfortable with discussion and management of problematic periods, birth control, and sexual activity. You also should be comfortable with counseling your patients on sexually transmitted disease (STD) prevention and other preventive tools, such as the human papillomavirus (HPV) vaccine.

I want pediatricians to routinely discuss the HPV vaccine with their patients and parents. The HPV vaccine is ideally given to young women before they are sexually active, as early as age 9 years. By the time most girls see a gynecologist for the first time, they are already sexually active and have already been exposed to HPV.

Pediatricians can help by encouraging parents to vaccinate their 9- to 13-year-olds. This discussion also should be taking place with parents of boys.

I realize that there is a wide range in how pediatricians practice. Some feel completely comfortable with gynecologic care in this age group and will perform gynecologic exams, STD testing, and prescribe birth control if necessary. Others might have the discussion and then refer if an exam or prescription for birth control is required. Others may not even feel comfortable having the discussion. So I think gynecologic referral of a patient in this age group is based on the comfort level of the pediatrician.

If you do refer to a gynecologist, you can help prepare a girl by letting her know what to expect. For example, if a girl is being sent for evaluation of vaginal discharge, the patient needs to understand that she is going to have an internal examination with a speculum. I have seen several young women for evaluation of this problem who were surprised that I had to examine them. Discharge cannot be appropriately evaluated simply by talking to the patient. So you can alleviate a lot of anxiety by explaining the exam to the patient ahead of time.

On the other hand, not every young woman needs to be examined during her first gynecologist visit. If her initial appointment is a discussion regarding menstrual cycles or birth control, I often just take a history to establish rapport with the patient. I often want to do this in private, without a parent, so that I can comfortably ask questions about personal issues such as sexual activity. It is very helpful if you can prepare the parent ahead of time that this private discussion will need to take place.

Several physician organizations provide recommendations and other guidance for management of these patients. The American Academy of Pediatrics provides relevant resources for pediatricians. For example, in September 2010, it published a Clinical Report on Gynecologic Examination for Adolescents in the Pediatric Office Setting (http://aappolicy.aappublications.org/cgi/content/full/pediatrics;126/3/583

You also might consider consulting with colleagues, including an ob.gyn. or a pediatrician who is fellowship trained in adolescent pediatrics.

It is important for pediatricians to recommend that their female patients seek gynecologic care by age 18 years at the latest. However, there is a role for gynecologic care as early as age 14 or 15 years in this patient population if a teenager is sexually active, is considering becoming sexually active, or has problems with her menstrual period.

Make it a policy to take the gynecologic history with the patient without the parent being present, starting at the age of 14 years or earlier, on an individualized basis. Asking the parent to leave the room as a part of routine practice makes this discussion far easier.

Start your consultation by asking specific questions about the girl's menstrual period. Oftentimes, their periods are irregular, painful, or heavier/longer than they think is normal. If this is the case, it is appropriate to refer your patient to a gynecologist. Also refer your patient if she expresses an interest in seeing a gynecologist for any reason.

Ask about boyfriends, sexual activity, and birth control. Often, girls do not want their parents to know about their sexual activity. I recommend you tell parents that you routinely recommend referral to a gynecologist at a certain age to address menstrual issues. This is an easy way to bring up the subject without making the patient or parent feel uncomfortable.

As a general pediatrician, you can manage this type of patient if you feel comfortable with discussion and management of problematic periods, birth control, and sexual activity. You also should be comfortable with counseling your patients on sexually transmitted disease (STD) prevention and other preventive tools, such as the human papillomavirus (HPV) vaccine.

I want pediatricians to routinely discuss the HPV vaccine with their patients and parents. The HPV vaccine is ideally given to young women before they are sexually active, as early as age 9 years. By the time most girls see a gynecologist for the first time, they are already sexually active and have already been exposed to HPV.

Pediatricians can help by encouraging parents to vaccinate their 9- to 13-year-olds. This discussion also should be taking place with parents of boys.

I realize that there is a wide range in how pediatricians practice. Some feel completely comfortable with gynecologic care in this age group and will perform gynecologic exams, STD testing, and prescribe birth control if necessary. Others might have the discussion and then refer if an exam or prescription for birth control is required. Others may not even feel comfortable having the discussion. So I think gynecologic referral of a patient in this age group is based on the comfort level of the pediatrician.

If you do refer to a gynecologist, you can help prepare a girl by letting her know what to expect. For example, if a girl is being sent for evaluation of vaginal discharge, the patient needs to understand that she is going to have an internal examination with a speculum. I have seen several young women for evaluation of this problem who were surprised that I had to examine them. Discharge cannot be appropriately evaluated simply by talking to the patient. So you can alleviate a lot of anxiety by explaining the exam to the patient ahead of time.

On the other hand, not every young woman needs to be examined during her first gynecologist visit. If her initial appointment is a discussion regarding menstrual cycles or birth control, I often just take a history to establish rapport with the patient. I often want to do this in private, without a parent, so that I can comfortably ask questions about personal issues such as sexual activity. It is very helpful if you can prepare the parent ahead of time that this private discussion will need to take place.

Several physician organizations provide recommendations and other guidance for management of these patients. The American Academy of Pediatrics provides relevant resources for pediatricians. For example, in September 2010, it published a Clinical Report on Gynecologic Examination for Adolescents in the Pediatric Office Setting (http://aappolicy.aappublications.org/cgi/content/full/pediatrics;126/3/583

You also might consider consulting with colleagues, including an ob.gyn. or a pediatrician who is fellowship trained in adolescent pediatrics.

It is important for pediatricians to recommend that their female patients seek gynecologic care by age 18 years at the latest. However, there is a role for gynecologic care as early as age 14 or 15 years in this patient population if a teenager is sexually active, is considering becoming sexually active, or has problems with her menstrual period.

Make it a policy to take the gynecologic history with the patient without the parent being present, starting at the age of 14 years or earlier, on an individualized basis. Asking the parent to leave the room as a part of routine practice makes this discussion far easier.

Start your consultation by asking specific questions about the girl's menstrual period. Oftentimes, their periods are irregular, painful, or heavier/longer than they think is normal. If this is the case, it is appropriate to refer your patient to a gynecologist. Also refer your patient if she expresses an interest in seeing a gynecologist for any reason.

Ask about boyfriends, sexual activity, and birth control. Often, girls do not want their parents to know about their sexual activity. I recommend you tell parents that you routinely recommend referral to a gynecologist at a certain age to address menstrual issues. This is an easy way to bring up the subject without making the patient or parent feel uncomfortable.

As a general pediatrician, you can manage this type of patient if you feel comfortable with discussion and management of problematic periods, birth control, and sexual activity. You also should be comfortable with counseling your patients on sexually transmitted disease (STD) prevention and other preventive tools, such as the human papillomavirus (HPV) vaccine.

I want pediatricians to routinely discuss the HPV vaccine with their patients and parents. The HPV vaccine is ideally given to young women before they are sexually active, as early as age 9 years. By the time most girls see a gynecologist for the first time, they are already sexually active and have already been exposed to HPV.

Pediatricians can help by encouraging parents to vaccinate their 9- to 13-year-olds. This discussion also should be taking place with parents of boys.

I realize that there is a wide range in how pediatricians practice. Some feel completely comfortable with gynecologic care in this age group and will perform gynecologic exams, STD testing, and prescribe birth control if necessary. Others might have the discussion and then refer if an exam or prescription for birth control is required. Others may not even feel comfortable having the discussion. So I think gynecologic referral of a patient in this age group is based on the comfort level of the pediatrician.

If you do refer to a gynecologist, you can help prepare a girl by letting her know what to expect. For example, if a girl is being sent for evaluation of vaginal discharge, the patient needs to understand that she is going to have an internal examination with a speculum. I have seen several young women for evaluation of this problem who were surprised that I had to examine them. Discharge cannot be appropriately evaluated simply by talking to the patient. So you can alleviate a lot of anxiety by explaining the exam to the patient ahead of time.

On the other hand, not every young woman needs to be examined during her first gynecologist visit. If her initial appointment is a discussion regarding menstrual cycles or birth control, I often just take a history to establish rapport with the patient. I often want to do this in private, without a parent, so that I can comfortably ask questions about personal issues such as sexual activity. It is very helpful if you can prepare the parent ahead of time that this private discussion will need to take place.

Several physician organizations provide recommendations and other guidance for management of these patients. The American Academy of Pediatrics provides relevant resources for pediatricians. For example, in September 2010, it published a Clinical Report on Gynecologic Examination for Adolescents in the Pediatric Office Setting (http://aappolicy.aappublications.org/cgi/content/full/pediatrics;126/3/583

You also might consider consulting with colleagues, including an ob.gyn. or a pediatrician who is fellowship trained in adolescent pediatrics.

President Obama's budget proposal for a two-year, $54 billion extension of the temporary fix to the reimbursement rate that Medicare pays doctors is getting a mixed reception from doctors as well as legislators on Capitol Hill.

"It's not ideal, but it's better than what we've been dealing with," says Ron Greeno, MD, SFHM, chief medical officer for Cogent Healthcare, and a member of SHM's Public Policy Committee. "The question is, will it remain part of the budget that gets passed?"

Last year, Congress approved five temporary extensions preventing draconian rate cuts mandated by Medicare's sustainable growth rate (SGR) formula, including a one-year, $19 billion extension passed with bipartisan support during the lame-duck session. The new proposal would further delay the cut, now at 25%, until September 2013. To pay for the patch, the budget suggests $62 billion in cuts that would transfer more of the Medicaid burden to states, recoup "erroneous" payments to insurers, and speed the process of getting generic drugs to market at the expense of major pharmaceutical companies, among other targets.

Republicans, however, have objected to the spend-now, save-later mechanism paying for the fix, with spending over two years counterbalanced by projected savings over an entire decade. And the proposal is silent on how the fix would be funded for the eight years beyond 2013, an extension the budget suggests would require an additional $316 billion.

Both Democrats and Republicans agree that the current SGR formula is unworkable. But Dr. Greeno says neither party wants to make a move that would add hundreds of billions to the debt amid heightened concern over the rising deficit.

"I think we need to change the way we pay, and I haven't figured out exactly how," Sen. Tom Coburn (R-Okla.) told The Hospitalist in an interview earlier this month. "But the SGR's a joke; it's never worked. It was a gimmick from the time it started in 1997 forward. It's never going to work."

Nevertheless, Republicans like Sen. Coburn have signaled that they understand allowing the rate cut to take place is untenable. "What I would tell your physicians is … they won't see any cuts, but they're not going to see any increases," he said. "The country is broke."

If Congress ultimately agrees to a two-year solution, Dr. Greeno says, it could buy the administration some wait-and-see time amid ongoing efforts aimed at repealing parts of the healthcare reform law or having it declared unconstitutional. A two-year extension also could buy more time for the Centers for Medicare & Medicaid Services' new Center for Medicare and Medicaid Innovation to figure out how to transition out of a total fee-for-service healthcare environment. "But that," Dr. Greeno says, "is going to take years."

President Obama's budget proposal for a two-year, $54 billion extension of the temporary fix to the reimbursement rate that Medicare pays doctors is getting a mixed reception from doctors as well as legislators on Capitol Hill.

"It's not ideal, but it's better than what we've been dealing with," says Ron Greeno, MD, SFHM, chief medical officer for Cogent Healthcare, and a member of SHM's Public Policy Committee. "The question is, will it remain part of the budget that gets passed?"

Last year, Congress approved five temporary extensions preventing draconian rate cuts mandated by Medicare's sustainable growth rate (SGR) formula, including a one-year, $19 billion extension passed with bipartisan support during the lame-duck session. The new proposal would further delay the cut, now at 25%, until September 2013. To pay for the patch, the budget suggests $62 billion in cuts that would transfer more of the Medicaid burden to states, recoup "erroneous" payments to insurers, and speed the process of getting generic drugs to market at the expense of major pharmaceutical companies, among other targets.

Republicans, however, have objected to the spend-now, save-later mechanism paying for the fix, with spending over two years counterbalanced by projected savings over an entire decade. And the proposal is silent on how the fix would be funded for the eight years beyond 2013, an extension the budget suggests would require an additional $316 billion.

Both Democrats and Republicans agree that the current SGR formula is unworkable. But Dr. Greeno says neither party wants to make a move that would add hundreds of billions to the debt amid heightened concern over the rising deficit.

"I think we need to change the way we pay, and I haven't figured out exactly how," Sen. Tom Coburn (R-Okla.) told The Hospitalist in an interview earlier this month. "But the SGR's a joke; it's never worked. It was a gimmick from the time it started in 1997 forward. It's never going to work."

Nevertheless, Republicans like Sen. Coburn have signaled that they understand allowing the rate cut to take place is untenable. "What I would tell your physicians is … they won't see any cuts, but they're not going to see any increases," he said. "The country is broke."

If Congress ultimately agrees to a two-year solution, Dr. Greeno says, it could buy the administration some wait-and-see time amid ongoing efforts aimed at repealing parts of the healthcare reform law or having it declared unconstitutional. A two-year extension also could buy more time for the Centers for Medicare & Medicaid Services' new Center for Medicare and Medicaid Innovation to figure out how to transition out of a total fee-for-service healthcare environment. "But that," Dr. Greeno says, "is going to take years."

President Obama's budget proposal for a two-year, $54 billion extension of the temporary fix to the reimbursement rate that Medicare pays doctors is getting a mixed reception from doctors as well as legislators on Capitol Hill.

"It's not ideal, but it's better than what we've been dealing with," says Ron Greeno, MD, SFHM, chief medical officer for Cogent Healthcare, and a member of SHM's Public Policy Committee. "The question is, will it remain part of the budget that gets passed?"

Last year, Congress approved five temporary extensions preventing draconian rate cuts mandated by Medicare's sustainable growth rate (SGR) formula, including a one-year, $19 billion extension passed with bipartisan support during the lame-duck session. The new proposal would further delay the cut, now at 25%, until September 2013. To pay for the patch, the budget suggests $62 billion in cuts that would transfer more of the Medicaid burden to states, recoup "erroneous" payments to insurers, and speed the process of getting generic drugs to market at the expense of major pharmaceutical companies, among other targets.

Republicans, however, have objected to the spend-now, save-later mechanism paying for the fix, with spending over two years counterbalanced by projected savings over an entire decade. And the proposal is silent on how the fix would be funded for the eight years beyond 2013, an extension the budget suggests would require an additional $316 billion.

Both Democrats and Republicans agree that the current SGR formula is unworkable. But Dr. Greeno says neither party wants to make a move that would add hundreds of billions to the debt amid heightened concern over the rising deficit.

"I think we need to change the way we pay, and I haven't figured out exactly how," Sen. Tom Coburn (R-Okla.) told The Hospitalist in an interview earlier this month. "But the SGR's a joke; it's never worked. It was a gimmick from the time it started in 1997 forward. It's never going to work."

Nevertheless, Republicans like Sen. Coburn have signaled that they understand allowing the rate cut to take place is untenable. "What I would tell your physicians is … they won't see any cuts, but they're not going to see any increases," he said. "The country is broke."

If Congress ultimately agrees to a two-year solution, Dr. Greeno says, it could buy the administration some wait-and-see time amid ongoing efforts aimed at repealing parts of the healthcare reform law or having it declared unconstitutional. A two-year extension also could buy more time for the Centers for Medicare & Medicaid Services' new Center for Medicare and Medicaid Innovation to figure out how to transition out of a total fee-for-service healthcare environment. "But that," Dr. Greeno says, "is going to take years."

David Meltzer, MD, PhD, a hospitalist and medical researcher at the University of Chicago, is one of 15 appointees who were named in January to the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), which was created by last year's Accountable Care Act to advise the federal government on clinical-effectiveness research (CER).

Dr. Meltzer, chief of UC's Division of Hospital Medicine and director of the Center for Health and Social Sciences in Chicago, has been active in a number of areas of advanced medical research, including technology assessment, CER, value-of-information research, and prioritization of the research agenda. One of his research topics has been whether hospitalists reduce length of stay and costs.

"Healthcare is a very complicated issue, for a bunch of reasons," he says. "It costs a lot of money, and it matters to a lot of people."

Last year's health-reform debate demonstrated how complicated it can be, with CER itself the target of some controversy. The challenge for PCORI is “to increase the information available to make the best choices regarding the application of medical treatments," he explains.

According to Dr. Meltzer, who also sits on the Congressional Budget Office's panel of health advisors, the reality is that physicians use medical evidence to guide treatment decisions every day. "But there are major holes in what we know and don't know. I would hope that PCORI will help to fill in those major holes more quickly," he adds.

If CER is done effectively, Dr. Meltzer says, hospitalists and other clinicians could find themselves and their patients more frequently involved in research and data generation, making it increasingly important to explain to patients why this sort of research is important.

"He has not only been a leader in hospital medicine, but also a noted health economist and researcher," says Margaret Fang, MD, a hospitalist at the University of California at San Francisco. "All of these skills will be vitally important when addressing issues in comparative-effectiveness research."

David Meltzer, MD, PhD, a hospitalist and medical researcher at the University of Chicago, is one of 15 appointees who were named in January to the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), which was created by last year's Accountable Care Act to advise the federal government on clinical-effectiveness research (CER).

Dr. Meltzer, chief of UC's Division of Hospital Medicine and director of the Center for Health and Social Sciences in Chicago, has been active in a number of areas of advanced medical research, including technology assessment, CER, value-of-information research, and prioritization of the research agenda. One of his research topics has been whether hospitalists reduce length of stay and costs.

"Healthcare is a very complicated issue, for a bunch of reasons," he says. "It costs a lot of money, and it matters to a lot of people."

Last year's health-reform debate demonstrated how complicated it can be, with CER itself the target of some controversy. The challenge for PCORI is “to increase the information available to make the best choices regarding the application of medical treatments," he explains.

According to Dr. Meltzer, who also sits on the Congressional Budget Office's panel of health advisors, the reality is that physicians use medical evidence to guide treatment decisions every day. "But there are major holes in what we know and don't know. I would hope that PCORI will help to fill in those major holes more quickly," he adds.

If CER is done effectively, Dr. Meltzer says, hospitalists and other clinicians could find themselves and their patients more frequently involved in research and data generation, making it increasingly important to explain to patients why this sort of research is important.

"He has not only been a leader in hospital medicine, but also a noted health economist and researcher," says Margaret Fang, MD, a hospitalist at the University of California at San Francisco. "All of these skills will be vitally important when addressing issues in comparative-effectiveness research."

David Meltzer, MD, PhD, a hospitalist and medical researcher at the University of Chicago, is one of 15 appointees who were named in January to the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), which was created by last year's Accountable Care Act to advise the federal government on clinical-effectiveness research (CER).

Dr. Meltzer, chief of UC's Division of Hospital Medicine and director of the Center for Health and Social Sciences in Chicago, has been active in a number of areas of advanced medical research, including technology assessment, CER, value-of-information research, and prioritization of the research agenda. One of his research topics has been whether hospitalists reduce length of stay and costs.

"Healthcare is a very complicated issue, for a bunch of reasons," he says. "It costs a lot of money, and it matters to a lot of people."

Last year's health-reform debate demonstrated how complicated it can be, with CER itself the target of some controversy. The challenge for PCORI is “to increase the information available to make the best choices regarding the application of medical treatments," he explains.

According to Dr. Meltzer, who also sits on the Congressional Budget Office's panel of health advisors, the reality is that physicians use medical evidence to guide treatment decisions every day. "But there are major holes in what we know and don't know. I would hope that PCORI will help to fill in those major holes more quickly," he adds.

If CER is done effectively, Dr. Meltzer says, hospitalists and other clinicians could find themselves and their patients more frequently involved in research and data generation, making it increasingly important to explain to patients why this sort of research is important.

"He has not only been a leader in hospital medicine, but also a noted health economist and researcher," says Margaret Fang, MD, a hospitalist at the University of California at San Francisco. "All of these skills will be vitally important when addressing issues in comparative-effectiveness research."